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ABSTRACT
The microbiome forms an integral part of the gut microenvironment. Once ignored,
the topic has gained momentum in research during the past decade, where studies have
strongly suggested the association of microbiota with health and a misbalance thereof, to
many disease conditions ranging from inflammation and colitis to diabetes, obesity and
colon cancer. The Human Microbiome Project (HMP, NIH common fund - 2008) has used
a variety of high throughput analyses in order to study gut microbiota in health. The
consortium has so far been able to isolate and characterize more than 1,300 reference
bacterial strains from the human body. The large amount of data generated has led to a
baseline need to address the implications of different microbial members, or groups
thereof, in health and disease. The microorganisms residing in the gut comprise of bacteria,
archaea, fungi and viruses that are distributed throughout the length of the gastrointestinal
tract. While there will be limitations to studying all types of microorganisms owing to their
overwhelming numbers and types, our study is focused only on bacterial populations of the
gut, and for the purpose of convenience, terms of gut microbiota/microbiome will be used
for describing gut bacteria pertaining to the mice used in our study. The overall purpose
of this study is to determine the effects of alterations in the gut microbiome on tumor
development and inflammation, and if it leads to recolonization of the gut by altered
bacterial communities. The working hypothesis was that an alteration of bacterial
microbiome occurs during tumorigenesis and manipulation of the gut microbiome
externally exacerbates the clinical symptoms associated with intestinal cancer, leading
vi

to higher gut and systemic inflammation. Specific aim 1 studied the composition of gut
microbiota during the stages of tumor initiation and progression. It aimed at studying the
gut microbial profiles pertaining to bacteria that reside inside the gut of the ApcMin/+ mice
during normal conditions and comparing it to control mice. Among the different bacterial
phyla residing in the murine gut, the Bacteroidetes and Firmicutes comprised of dominant
bacterial populations. Specific aim 2 studied the effects of external manipulation of the gut
microbiome on gut health and tumorigenesis. The manipulation of the gut microbial
community was used to help elucidate how alterations in the gut microbiome effect the
intestinal tumor and mucus production outcomes along with their effects on the gut health
in measurable terms. Specific aim 3 studied the altered inflammatory response of the mouse
gut with respect to relative abundances of the Bacteroidetes and Firmicutes bacterial phyla
populations.
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CHAPTER 1
INTRODUCTION
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The topic of gut microbiome has recently gained attention due to research
suggesting its significant role in not only maintenance of gut health but also in disease
conditions such as obesity, diabetes, arthritis, colitis and cancers of the digestive system
(Cho, Carter, Harari, & Pei, 2014; Dziarski, Park, Kashyap, Dowd, & Gupta, 2016;
Kabeerdoss, Sandhya, & Danda, 2015; Knip and Siljander (2016)). The gut microbiome
comprises of around 500-1000 species and a genetic diversity which has 100-fold more
genes than humans (Dugas, Fuller, Gilbert, & Layden, 2016).
Another field that aims at answering the questions on gut microbiome and its links
to health and disease is the usage of probiotics including one or more important bacteria.
The bacteria Lactobacillus acidophilus has been implicated in a significant suppression of
colon tumor incidence and size and a reduction in pro-inflammatory cytokines such as
TNF-α and IFN-γ (Perdigon, Valdez, & Rachid, 1998; Urbanska, Bhathena, Martoni, &
Prakash, 2009). Some studies also state that the link between the microbiome and the actual
development of polyps in the gut is solely linked through the erosion of the gut lumen
microenvironment and the resulting inflammation (Dianda et al., 1997).
An altered microbiome has been previously linked to inflammatory bowel disease
and colorectal cancer. However, we still lack the knowledge of a characterizing the gut
microbiome that relates to health or disease condition. An early event of inflammatory
insult to the gut can very well result in tumorigenesis when combined with processes of
bacterial DNA damage and chromatin alterations (Zhu, Michelle Luo, Jobin, & Young,
2011). Studies on mouse models such as the IL-10-/- have demonstrated a protective role
of the presence of gut microbiome on inflammation, where the WT mice were rendered
protected against inflammation in the gut while the germ-free (no microbiome) animals
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developed colitis (S. Wu et al., 2009). It should be noted here that germ-free animals may
not represent the human gut as an individual can never be completely without microbiome
in the gut. From the perspective of any given disease state that can be linked to microbiome,
the basis of its linkage can only be an altered microbiome. It should also be noted that the
process of inflammation is the one that alters the microbiome (Uronis & Jobin, 2009),
although inflammation alone is not sufficient to promote colorectal cancer and altered
microbiota works hand in hand with inflammatory insults that eventually lead to cancer
(Arthur & Jobin, 2013). The gut microbiome has been shown to complement AOM and
DSS mouse models in causing tumorigenesis, but is yet to be elucidated if it is the increase
or loss of certain bacterial populations that lead to development of polyps (Zackular et al.,
2013). It is, however, not known what effect the microbial dysbiosis has at different stages
of progression of tumorigenesis in the mouse, or if it leads to different consequences in
normal versus tumorigenic conditions.

What is unknown?
Studies are needed to characterize the interplay between the gut microbiome, inflammation
and cancer. Another aspect which may be helpful in correctly defining the microbiome and
inflammation-to-cancer axis is the progression of alterations in the microbiome with
worsening disease pathology. Of all the diseases that are affected by a change or loss of
gut microbiome, cancer of the small and large intestine is clearly the one which can be
physically and physiologically related to the presence of alterations in gut microbiome
community.

3

AIM 1: Examine the gut microbiome composition during tumor initiation and
development in ApcMin/+ mice.

Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial
lining that, in turn, leads to more and more inflammatory processes taking place inside the
gut microenvironment (Saxena et al., 2012; Wang & Zhang, 2015). Our previous study on
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice
demonstrated microbiota profiles that were clearly altered during tumorigenesis (data not
published). The alterations mainly pertained to the altered percentages of the Firmicutes
and Bacteroidetes bacterial phyla during inflammation-induced tumorigenesis in the mice
(Figure 1). As opposed to externally administered chemically-induced tumorigenesis in
mice, the microbiota has not been studied with respect to a spontaneously induced
tumorigenesis such as that in the ApcMin/+ mouse. It was recently concluded that an
alteration of gut microbiome precedes polyposis in the ApcMin/+ mouse (Son et al., 2015).
Also, it has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor
load and anemia with a higher infiltration of inflammatory cells specifically at advanced
stages as compared to germ-free animals, indicating that a mere modulation of gut
microbiome profiles can abrogate the disease condition in the gut (Y. Li et al., 2012).
However, there are no studies that study the gut microbiome with respect to gut
inflammation and tumorigenesis in an age/time- dependent manner. Therefore, the first aim
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of the present study was directed towards characterization of alterations of microbiome
profiles from early to later stages of tumorigenesis in an ApcMin/+ mouse model.

Hypothesis: The gut microbiota in ApcMin/+ mice exhibits a higher percentage of
Firmicutes bacterial phylum and a lower percentage of Bacteroidetes, along with the
reduction in overall bacterial diversity during onset of tumorigenesis when compared to
the WT mice. Furthermore, the percentage of Firmicutes increases, while overall diversity
decreases during the progression of tumorigenesis.

AIM 1.1: Study of the gut microbiome profiles during intestinal tumor initiation.
Hypothesis 1.1: The microbiome profile of ApcMin/+ mice exhibits a higher percentage of
Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to WT mice at
initiation of tumor development. The overall microbial diversity decreases lower in
ApcMin/+ mice as compared to their WT counterparts.

AIM 1.2: To study the profile of the gut microbiome during the progression of intestinal
tumor development.
Hypothesis 1.2: The microbiome profile of ApcMin/+ mice exhibit a higher percentage of
Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to their WT
counterparts during tumor progression. Firmicutes population is higher during later stages
of tumorigenesis as compared to initial stages of tumorigenesis. Also, the microbial
diversity values are lower in ApcMin/+ mice during tumor progression as compared to WT
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mice, and within ApcMin/+ mice at later stages of tumor development as compared to their
initial stages of tumorigenesis.

AIM 2: Determine if gut microbiome manipulation can regulate the ApcMin/+ mouse
health and tumorigenesis.

Rationale: The mucus layer tends to thickness with increased diversity of the microbiota
(Jakobsson et al., 2015). Our preliminary data from a study on chronic inflammationinduced colon cancer using APNKO mice suggested that the gut microbiota changes in a
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as
compared to others (such as Bacteroidetes). It has not been studied yet as to whether there
is a relation between the altered percentages of especially the Firmicutes and Bacteroidetes
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that
the mucus layer provides a source of nutritional carbon and therefore energy to some of
the intestinal flora that are able to lyse the glycans present in the mucus, making the interrelationship between the gut bacteria and the mucus layer really important (Kaur et al.,
2015). Also, the metabolites produced by these microbes also influence the differentiation
and function of the epithelial and immune cells in the intestinal mucosa (Kato, Kawamoto,
Maruya, & Fagarasan, 2014; Shan et al., 2013). The regulation of the mucin gene
expression as well as mucus production have been shown to be two levels at which the gut
microbial community may modulate mucins (Comelli et al., 2008). Our recent study (Kaur,
et al., 2015) also suggested that a reduction in the secretory mucin profile is associated with
an inflammatory phenotype of the gut (Figure 4). Therefore, the present aim was directed
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at knowing the mucus-producing phenotypes of the cells lining the gut of the experimental
animals in relation to the changing profiles of the gut microbiota.

Hypothesis: Manipulation of the gut microbiota leads to a decrease in gut health and an
increase in tumor number and size in the ApcMin/+ mouse. Furthermore, manipulation of the
gut microbiota decreases goblet cell number in the intestine and colon.

AIM 2.1: To determine if manipulation of gut microbiome through antibiotic
administration affects disease prognosis in the ApcMin/+ mouse.
Hypothesis 2.1: The manipulation of gut microbiome by externally administered
antibiotics leads to a worsening of disease prognosis in the experimental mice.

AIM 2.2: To determine if manipulation of gut microbiome through antibiotic
administration affects tumor number and size in the ApcMin/+ mouse.
Hypothesis 2.2: The manipulation of the gut microbiome by externally administered
antibiotics leads to an increase in tumor number and size in the ApcMin/+ mice.

AIM 2.3: To determine if gut microbiome manipulation effects goblet cell numbers in
small intestine and colon of ApcMin/+ mice as compared to WT mice.
Hypothesis 2.3: The manipulation of the gut microbiome by externally administered
antibiotics leads to a reduction in goblet cell numbers in the intestine and colon of ApcMin/+
mice.
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AIM 3: Determine if the relative abundance of Bacteroidetes and Fimicutes bacterial
populations is associated with intestinal and systemic inflammation in the ApcMin/+
mouse.

Rationale: The induction of cancer in the gut by chronic inflammation has always
indicated towards the importance of underlying altered inflammatory processes (Wang &
Zhang, 2015). Different agents that have been documented to be effective against tumors
and cancers are the agents that function by downregulating important inflammatory
pathways and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction
of macrophage infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael,
2011; Murphy, Davis, McClellan, Gordon, & Carmichael, 2011; Ritland et al., 1999). It
has also been shown that the intestinal commensal bacteria plays a role in the development
of gut microenvironmental immune system comprising both the humoral and cellular
components and maintains the protective steady state immune function throughout life
(Cebra, 1999; Talham, Jiang, Bos, & Cebra, 1999). It may be more appropriate to say that
any alteration in comparative numbers of certain bacteria often lead to upregulation or
downregulation of certain inflammatory pathways. The systemic release of microbial
products as a result of the manipulation of the gut epithelium invokes an IL-23 response
and a further IL-17 response in order to neutralize further invasion by the microbes, and
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih et al., 2014).
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides
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fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10
cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon
cancer (W. Wu et al., 2015). Inflammation, which is an integral part of tumorigenesis
should therefore, may strongly be correlated with a reduced bacterial diversity or numbers.

Hypothesis: An increase in the population of Firmicutes bacteria and/or a reduction in the
population of Bacteroidetes leads to a higher inflammatory response in both the intestinal
tissue and systemic circulation.

AIM 3.1: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate intestinal tissue inflammation in ApcMin/+ mice.
Hypothesis 3.1: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations increases the inflammatory cellular infiltration into the mucosa of the intestinal
tissue of the experimental mice.

AIM 3.2: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate intestine-secreted IL-1β, IL-17 and TNF-α in ApcMin/+ mice.
Hypothesis 3.2: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations increases the intestine-secreted IL-1β, IL-17 and TNF-α levels in the
experimental mice.
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AIM 3.3: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate systemic levels of cytokines IL-1β, IL-17 and TNF-α in ApcMin/+ mice.
Hypothesis 3.3: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations increases systemic levels of IL-1β, IL-17 and TNF-α cytokines in the
experimental mice.

Working Model

Figure 1.1. Working Model: Figure illustrating the working model for the study where
the three different aims have been depicted with their respective factors measured during
the study.
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The central idea of the present study is to study the role of gut microbiota (bacterial) in
tumorigenesis, mucus producing phenotype and inflammation. In order to study this, we
used the ApcMin/+ model of intestinal cancer. The ApcMin/+ mouse model is raised from the
C57BL/6 background where a point mutation on codon 850 of the Apc (Adenomatous
Polyposis Coli) gene leads to spontaneous development of polyps (adenomas) in the
intestinal mucosa (Zhang et al., 2015). The mutation is responsible for the production of a
truncated APC protein (2843 amino acids) that lacks its C-terminal domains. The protein
functions to downregulate the Wnt signaling pathway by binding to and promoting the
destruction of the β-catenin protein. It has been shown that altered interactions between the
gut microbiota and colonic mucosa precede polyposis in the ApcMin/+ mouse (Son, et al.,
2015). Using the basis of an altered gut microbiota preceding polyposis, we are trying to
delve further into the processes that are hampered by alterations in the gut microbiota,
which can be used to elucidate the ways in which the gut microbiota affects tumorigenesis.
The first aim of the study was directed towards examining the composition of gut
microbiome during tumor initiation and development in the ApcMin/+ mouse. This aim acted
as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of
tumorigenesis. Previous studies have demonstrated an alteration in gut microbiota to be
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even
immune system. Conditions such as Crohn’s disease and obesity have implicated gut
bacterial dysbiosis in pathogenesis (Chan, Kumar, & Mendall, 2015; Mai, Colbert, Perkins,
Schatzkin, & Hursting, 2007). The characterization of the gut microbiome in the
experimental ApcMin/+ mice helped define the abundance of different bacterial species in
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the gut and their relative diversity values during the initiation and progression of
tumorigenesis.
The second aim of the study was directed towards elucidating the role of an altered
microbiome on pathology of the experimental animals. Antibiotics were administered to
experimental mice in order to perturb the gut microbiota during the initial and progressive
stages of tumorigenesis. The use of antibiotics not only help get rid of pathogenic bacteria
but also deplete related micro-organisms, which fail to return to normal levels even long
after the antibiotic usage subsides (Cresci & Bawden, 2015). This aim was directed towards
helping in elucidating the effect of alterations in microbiome in terms of their abundance
and diversity on the disease condition of the animals. This aim was also being directed
towards knowing if the tumor numbers and size are related to the microbiome and its
alterations. The third part of this aim helped elucidate the effects of altered gut microbiome
on expression of goblet cells in the intestine and colon of mice. Our previous study (Saxena
et al., 2013) has demonstrated that a reduction in goblet cell numbers leads to worsened
disease pathology and reduced protection against chronic inflammation-induced colon
cancer. A reduction in the number of mucus-producing goblet cells may also be altered in
the ApcMin/+ model and further worsen the disease state once they are administered
antibiotics.
The third aim of the present study was aimed at demonstrating the effects of an
altered microbiome on the inflammatory status of the experimental animals. Inflammation
is an important route through which alterations in gut microbiota affect the overall milieu
of inflammatory processes closely associated with the gut. The inflammatory response,
along with being systemic, has also been demonstrated to occur at a more localized level
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such as the alterations in gut microbiota leading to increased levels of pro-inflammatory
cytokines such as IL-1β and TNF-α (Singh, Yeoh, Carvalho, Gewirtz, & Vijay-Kumar,
2015). In the first part of aim 3 was to study the effects of a changed microbiome on tissuelocalized inflammation and infiltration occurring at the level of intestinal mucosa. The
second part of the aim helped study the effects of microbiome manipulation on intestinesecreted pro-inflammatory cytokines. Whether the inflammatory effect is systemic or not,
was elucidated through the third part of this aim where systemic levels of pro-inflammatory
cytokines were measured.
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CHAPTER 2
LITERATURE REVIEW
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2.1 The ApcMin/+ mouse model
The ApcMin/+ mouse model is widely used by researchers to study gut inflammation and
cancer. The ApcMin/+ mouse model is raised from the C57BL/6 background where a point
mutation on codon 850 of the Apc (Adenomatous Polyposis Coli) gene leads to
spontaneous development of polyps (adenomas) in the intestinal mucosa (Zhang, et al.,
2015). The mutation is responsible for the production of a truncated APC protein (2843
amino acids) that lacks its C-terminal domains. The protein functions to downregulate the
Wnt signaling pathway by binding to and promoting the destruction of the β-catenin
protein. An altered APC protein thus leads to, apart from the development of intestinal
polyps, dysregulation of processes like cell adhesion, cell migration, chromosome
segregation and stability (McCart, Vickaryous, & Silver, 2008).

The ApcMin/+ mouse model represents the human cancer syndrome called the
Familial Adenomatous Polyposis (FAP) where the human intestine may contain several
thousand adenomas by the age of 20-30 years, which corresponds to ~4-6 weeks in mouse.
The ApcMin/+ mouse exhibits more than 50 tumors along the entire length of the intestine
and rarely live past the age of 21-22 weeks (Shoemaker, Gould, Luongo, Moser, & Dove,
1997), which corresponds to ~60 years of age in humans. Since all intestinal tumors in B6
Min/+ mice are benign adenomas, the premature death of these animals is associated with
secondary effects of tumor growth, including severe, chronic anemia and intestinal
blockage (Shoemaker, Moser, & Dove, 1995).
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2.2 The Gut Microbiome
The gut microbiome is an integral and an important symbiotic system present in the gut,
which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal tract
throughout its length. The gut bacteria itself comprises a major percentage of the total gut
microbiome, where its numbers are in trillions. While the stomach and duodenum contain
about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the jejunum and
ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria (Cresci &
Bawden, 2015). The microbiome acts advantageous for the gut such that it regulates gut
epithelial and endocrine cellular structure (Uribe, Alam, Johansson, Midtvedt, &
Theodorsson, 1994). The commensal bacterium B. thetaiotaomicron VPI-5482, for
example, which is a member of the gut flora, has been linked to the functional processes
of the gut such as nutrition absorption, mucosal barrier function, metabolism, angiogenesis
and postnatal intestinal maturation (Hooper & Gordon, 2001; Hooper et al., 2001).
Previously, many studies have demonstrated an alteration in gut microbiota to be
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even
immune system. Conditions such as Crohn’s disease and obesity have implicated gut
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The highest
bacterial load is found in the distal small intestinal tract and colon - areas commonly found
to be associated with disease conditions (Hooper, Midtvedt, & Gordon, 2002; Kanauchi,
Mitsuyama, Araki, & Andoh, 2003). It was not clear if the bacterial dysbiosis is a cause or
consequence of the disease until recently when it was shown that alterations in gut
microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). An altered gut
microbiome can cause inflammation ranging from acute bouts to chronically inflamed gut.
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An altered microbiome, which shifts from symbiotic to a more inflammation-inducing
`phenotype, leads to a vicious cycle of erosion of the gut epithelial lining that, in turn, leads
to more and more inflammatory processes taking place inside the gut microenvironment
(Saxena, et al., 2012; Zhang, et al., 2015). A need to address and characterize host-microbe
relations has been emphasized in recent years in order to elucidate the processes and factors
involved in the relationship between the gut microbiome and inflammation and related
tumorigenesis.
The intestinal epithelial lining has a strong relationship to the gut bacteria. The
bacterial flora of the intestine helps in digesting the food (especially carbohydrates) that
cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells
metabolize the short-chain fatty acids that result from the bacterial fermentation of the
undigested carbohydrates and use them as an energy source (Abreu, 2010).

2.3 Antibiotic usage, gut microbiome and inflammation
Antibiotic treatments that are usually used against digestive tract infections not only target
the pathogenic microbes but also the host-interactive useful microbes. It is already known
that the use of antibiotics, especially broad spectrum, not only help get rid of pathogenic
bacteria but also deplete related micro-organisms, which fail to return to normal levels even
long after the antibiotic usage subsides (Cresci & Bawden, 2015). Microbial diversity also
is seen to be reduced in the gut following antibiotic treatment which exerts detrimental
effects (Lofmark, Jernberg, Jansson, & Edlund, 2006).

17

Antibiotic usage can severely and permanently affect 30% of the microbial
population (Dethlefsen & Relman, 2011). Once the antibiotic treatment is stopped, and
some resilient bacteria repopulate the gut, the final state is never a complete replacement
of the initial state (Francino, 2015). Any early antibiotic treatment in humans reduces the
overall diversity of the microbiota populations inside the gut which leads a dysbalance of
the inflammatory molecules in the body. The dysbalance between the Th1 and Th2
paradigm was at first thought to be the main culprit in bringing out the inflammatory effects
of the microbiota dysbalance. An increased Th1 activation was linked to harmful
inflammatory changes (Akdis & Akdis, 2009; Oboki, Ohno, Saito, & Nakae, 2008).
However recently, alterations in the gut microbiota have been linked to a dysregulation of
the regulatory T cell paradigm and their associated cytokines (Shen, Hu, Kang, Tang, &
Hong, 2014), where the regulation of this immunological pathway depends on the
relationship between the gut microbiota and the immune system. Different cocktails of
antibiotics administered to mice have led to an upregulation of either the Th2 or a Th17
response (Atarashi & Honda, 2011; Dimmitt et al., 2010), indicating that an alteration in
the gut microbiota may favor one pathway and downregulate another inflammatory
pathway. How the microbiota changes in the first place and then a subsequent change
occurs in the inflammatory pathways during spontaneous tumorigenesis is a question that
the present study aimed at answering via studying different stages of tumorigenesis.
Inflammation is an important route through which alterations in gut microbiota
affect the overall milieu of inflammatory processes closely associated with the gut. Gut
microbiota manipulation through antibiotic treatment has been shown to cause a decrease
in the expression of the Muc2 protein, a major component of the intestinal mucus layer
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(Dimmitt, et al., 2010). A thinning of the protective mucus layer leads to a direct contact
between the gut lining and the gut bacteria residing in the lumen, thereby triggering innate
immune responses and inflammation (Francino, 2015). The inflammatory response, along
with being systemic, also occurs at a more localized level such as the alterations in gut
microbiota leading to increased levels of pro-inflammatory cytokines such as IL-1β and
TNF-α (Vijay-Kumar, Carvalho, Aitken, Fifadara, & Gewirtz, 2010).
For the completion of aims 2 and 3, antibiotics were administered to the treatment
group of mice in three sets: 1). One cycle of antibiotic administration starting at 6 weeks
of age for 10 days and sacrifice at 8 weeks; 2). Two cycles of antibiotic administration
starting at 6 weeks and 10 weeks and sacrifice at 12 weeks; and 3). Three cycles of
antibiotic administration starting at 6, 10 and 14 weeks of age and sacrifice at 16 weeks.
Antibiotic administration at 6 weeks of age signified the manipulation of gut microbiome
at the onset of tumorigenesis. This stage of tumorigenesis is marked by a gradual increase
in the number of polyps in the small intestine (Puppa et al., 2011). Antibiotic administration
at 6 and 10 weeks of age helped define effects of microbiome altered at the beginning of
tumorigenesis (6 weeks) and then at the middle of the life span of experimental mice which
is marked by progression of tumor development resulting in more pronounced symptoms
of anemia and intestinal blockage. While the polyp number reaches a plateau, they only
increase in size during this stage and the animals continue to lose body weight (Puppa, et
al., 2011). Antibiotic treatment at 6, 10 and 14 weeks represented the alterations in
microbiome throughout the processes initiation of tumorigenesis. This stage is usually
marked by severe inflammation, continuation of tumor size and maximum weight loss
(Puppa, et al., 2011).
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2.4 Impact of antibiotics
Although antibiotics are used against pathogenic microbes, their usage affects other
microbial members of the community as well. The effects that are established as a result of
an altered microbiome can be long-lasting even after the antibiotic treatment has subsided
(Jakobsson, et al., 2015; Jernberg, Lofmark, Edlund, & Jansson, 2007). While the more
resilient bacteria are successful at returning to their pre-treatment levels, others are lost
indefinitely (Willing, Russell, & Finlay, 2011). Moreover, the occurrence of codependence between members of the community based on differential metabolite
production and utilization pathways leads to perturbation of members that are not
necessarily directly targeted by the antibiotic.
The direct and indirect effects of the antibiotics are brought about at different levels
and ways. The indirect effects are brought about by the changed gut microbiota. A change
in the bacterial population is known to cause a change in the downstream signaling by the
Pattern Recognition Receptors (PPRs) which help maintain epithelial integrity and repair
process, while change in some bacterial populations that bind to Toll-like receptors, such
as TLR4, are linked to an altered innate immune defenses (Willing, et al., 2011). A reduced
production of short-chain fatty acids (SCFAs) is also a common feature of human
metabolic profiles after antibiotic treatment (Romick-Rosendale et al., 2009; Yap et al.,
2008). Changes in bacterial populations also affects differentiation of certain immune
system molecules such as IL-17 and often lead to a dysregulation of the immune system
(Ivanov et al., 2009). More direct effects include undesirable inflammation of the gut such
as gastroenteritis (Barthel et al., 2003) and even dermatitis (J. Watanabe, Fujiwara,
Sasajima, Ito, & Sonoyama, 2010).
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The antibiotics used for the present study are neomycin, vancomycin and
ampicillin. The antibiotic neomycin is used against both Gram-positive and Gram-negative
bacteria. Being nephrotoxic, it is almost always prescribed to be consumed through the oral
route. Its primary method of action is binding the duplex of RNA of bacteria (Kaul & Pilch,
2002). The antibiotic is water-soluble and has a low toxicity for animals (Waksman &
Lechevalier, 1949). Vancomycin is an antibiotic which is used against Gram-positive
bacteria (Gonzalez, Rubio, Romero-Vivas, Gonzalez, & Picazo, 1999; Small & Chambers,
1990). It is not absorbed by the intestinal mucosa (Van Bambeke, 2006) and its acts by
inhibiting the cell wall formation of the Gram-positive bacteria by binding to the terminal
D-alanyl-D-alanine moieties of the N-acetyl glucosamine/N-acetyl muramic acid peptide
(Chakraborty et al., 2010). The antibiotic ampicillin is active against both Gram-positive
and Gram-negative bacteria and is usually no-toxic. It mechanism of action includes its
penetration into the bacterial cell wall and acting as an irreversible inhibitor of the enzyme
transpeptidase involved in the construction of the bacterial cell walls ultimately leading to
bacterial cell lysis.

2.5 Intestinal mucus layer
The gut lining is folded into tubular invaginations called the villi in the intestine and crypts
(of Leiberkuhn) in the colon. The gut lining is protected from the lumen microenvironment
by a single-cell layer comprising of absorptive enterocytes (which make most of the
epithelial cells), mucus-producing goblet cells, hormone-producing enteroendocrine cells
and Paneth cells that produce anti-microbial products in the gut (Abreu, 2010). The four
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types of the cells line the single-celled layer of the gut that faces the lumen. All the four
types of cell arise from the pluripotent stem cells that lie at the base of the crypts. The
differentiated cells that arise from the stem cells of the crypts slowly and continuously rise
towards the crypt apex from where the single-celled layer is regularly shed and renewed to
maintain a healthy gut, also providing the crypt with a feature of polarity.
The mucus in the small and large intestine is secreted by the goblet cells. It forms
the first line of defense between the gut lumen microenvironment and the underlying
epithelial layer and the submucosa. The mucin proteins in the gut mainly comprise of the
MUC2 and MUC5AC proteins. They have properties of forming gel like coating onto the
gut lumen once getting hydrated and form highly glycosylated proteins that are resistant to
the digestive environment of the gut (Koboziev, Reinoso Webb, Furr, & Grisham, 2014).
Changes in goblet cell function, secretion of mucins into the lumen and composition of this
mucus layer are shown to be altered by an altered microbiome (Deplancke & Gaskins,
2001). The mucus layer provides a balanced ecosystem for the resident and as well as
pathogenic bacteria in the intestinal lumen by acting as a source of nutrition, thus indicating
a homeostatic balance between the host gut microenvironment and the microbiome
associated with it (Aristoteli & Willcox, 2003). An alteration in one of them may render
the other dysfunctional. It is also said that the resident bacteria may inhibit the adherence
of pathogenic bacteria to the intestinal epithelial cells by increasing the production of
intestinal mucus (Mack, Ahrne, Hyde, Wei, & Hollingsworth, 2003; Mack, Michail, Wei,
McDougall, & Hollingsworth, 1999; Smirnova, Guo, Birchall, & Pearson, 2003).
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2.6 Mucus and gut microbiome
It has been shown that the mucus layer tends to thickness with increased diversity of the
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans
present in the mucus, making the inter-relationship between the gut bacteria and the mucus
layer really important (Kaur, et al., 2015). Also, the metabolites produced by these
microbes also influence the differentiation and function of the epithelial and immune cells
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et
al., 2015) also suggested that a reduction in the secretory mucin profile is associated with
an inflammatory phenotype of the gut. Inflammation, which is an integral part of
tumorigenesis should therefore, may strongly be correlated with a reduced bacterial
diversity or numbers. Moreover, both Gram-positive and Gram-negative bacteria are
known to enhance the intestinal mucin expression (Dohrman et al., 1998). The regulation
of the mucin gene expression as well as mucus production have been shown to be two
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008).
Gut microbiota manipulation through antibiotic treatment has been shown to cause a
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus
layer (Wlodarska et al., 2011). A thinning of the protective mucus layer leads to a direct
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering
innate immune responses and inflammation (Francino, 2015).
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2.7 Gut microbiome and ApcMin/+
Studies that work at elucidating the role of gut microbes in disease models, are limited,
especially due to the fact that most of the important gut bacteria are difficult to grow in a
laboratory setting making them unavailable for studying unless mammalian models are
used. However, there is evidence that the manipulation of the gut microbiome through diet
modulations, can alter the disease conditions such as those in Crohn’s disease and
Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse model
for studying gut diseases and their association with microbiota often report significant
changes in microbiome profiles of the large intestine, but also report that differences in the
polyps is only significant in the small intestine (Mai, et al., 2007) The detrimental effects
are also brought about via loss of certain colonizing bacterial species that are dependent on
other colonizers for processes such as nutritional interactions and removal of secondary
metabolites and toxic waste products (Belenguer et al., 2006), or through loss of useful coevolved processes brought about by the host-microbial co-dependence (Atarashi & Honda,
2011; Ferreira, Willing, & Finlay, 2011). There are no studies that study the gut
microbiome with respect to gut inflammation and tumorigenesis in an age/time- dependent
manner. It has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor
load and anemia with a higher infiltration of inflammatory cells specifically at advanced
stages as compared to germ-free animals, indicating that a mere modulation of gut
microbiome profiles can abrogate the disease condition in the gut (Y. Li, et al., 2012).
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2.8 Gut microbiome, inflammatory cytokines and tumorigenesis
It is a fact that till date, one of the most effective class of chemopreventive agents is the
non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in the gut by
chronic inflammation has always indicated towards the importance of underlying altered
inflammatory processes (Zhang, et al., 2015). Different agents that have been documented
to be effective against tumors and cancers are the agents that function by downregulating
important inflammatory pathways and pro-inflammatory cytokines. Apart from the usual
NSAIDs that function by downregulating the metabolism of the arachidonic acid through
the Cyclooxygenase (COX) pathways agents such as curcumin and quercetin exert their
chemopreventive effects through the downregulation of mRNA expression levels of proinflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of macrophage
infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 2011; Murphy,
Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999).
It has also been shown that the intestinal commensal bacteria play a role in the
development of gut microenvironmental immune system comprising both the humoral and
cellular components and maintains the protective steady state immune function throughout
life (Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any
alteration in the composition of the gut microbiome leads to a dysfunctional immune
system.
Certain bacterial species such as B. thetaiotaomicron bacterium have been
associated with the attenuation of pro-inflammatory responses by reducing the levels of the
pro-inflammatory cytokine IL-8 (Zhao et al., 2001).
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Comparative numbers of certain bacteria often lead to upregulation or
downregulation of certain inflammatory pathways. The systemic release of microbial
products as a result of the manipulation of the gut epithelium invokes an IL-23 response
and a further IL-17 response in order to neutralize further invasion by the microbes, and
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014).
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides
fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10
cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon
cancer (W. Wu, et al., 2015).
It is widely accepted that inflammation contributes to the development of cancer
and inflammatory cells have been noted in and around tumors (Hanahan & Weinberg,
2011). A relationship between inflammation and intestinal neoplasia is supported by the
facts that inflammatory bowel disease predisposes patients to intestinal carcinomas and
that the anti-inflammatory drugs aspirin (Baron et al., 2003), celecoxib (Bertagnolli et al.,
2006), and rofecoxib (Bertagnolli, et al., 2006), all have proven efficacy in preventing
human colorectal adenoma development.
Adenoma formation has been shown to increase following adoptive transfer of proinflammatory lymphocytes (Rao et al., 2006) and decreased after the adoptive transfer of
anti-inflammatory regulatory T-cells (Treg cells) (Erdman et al., 2005). Apart from direct
effects of inflammatory cells, adenomas are also known to be impaired by the absence of
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the molecule MyD88 which mediates the downstream inflammatory signaling as a
response to bacterial and viral products (Rakoff-Nahoum & Medzhitov, 2007). Proinflammatory pathways such as those involved with IL-17 secretion are associated with
many chronic inflammatory conditions such as asthma (Schnyder-Candrian et al., 2006)
and inflammatory bowel disease (Yen et al., 2006), along with colon carcinogenesis
(Langowski et al., 2006). IL-17, especially, has been denoted as a marker and mediator of
tumor angiogenesis (Langowski, et al., 2006). Over-expression of pro-inflammatory
factors such as IL-6, MCP-1, NF-ᴋB and IL-8 can aggravate tumors (Wang & Zhang,
2015).
Mechanisms of how the microbiome dysbiosis can lead to inflammation and
tumorigenesis is not clear, however, recent studies have shown that microbiota species such
as the Bacteroides fragilis and Escherichia coli can cause colorectal cancer by producing
virulence factors such as toxins and gene products (Arthur et al., 2012; S. Wu, et al., 2009).
It has been suggested that the interplay of inflammation and tumorigenesis is modulates
strongly by the gut microbiota but the mechanisms leading to the process have not
elucidated. Recently, some light has been shed on thei phenomena by a study which could
demonstrate the process of tumorigenesis to occur in germ-free mice when transplanted
with isolated gut microbiota from intestinal tumor-bearing mice (Zackular, et al., 2013)
In the context of the ApcMin/+ mouse model, the mutual interaction of macrophages
with cancer cells enhances production of inflammatory cytokines such as IL-1, IL-6 and
TNF-α that transform the tumor microenvironment so that it favors the survival, growth
and motility of cancer cells. Reduction in pro-inflammatory molecules such as MCP-1
leads to a decrease in the total polyp number and size in the ApcMin/+ mouse along with
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downregulating inflammatory processes in tumor tissues and surrounding tumor
microenvironment (McClellan, Davis, Steiner, Day, et al., 2012). An elevation in the
intestinal inflammatory cytokine (MCP-1, IL-1β, IL-6 and TNF-α) response occurs at 12
weeks of age as a result of the rapid increase in polyp number, which are further elevated
with increase in polyp size. A similar study by McClellan et al (2012) (McClellan, Davis,
Steiner, Enos, et al., 2012) shows an increased mRNA expression of MCP-1, IL-1β, IL-6
and TNF-α that is evident at 12 weeks of age and is consistent with the increase in polyp
number that occurs at this time. After the age of 12 weeks which is associated with the
largest number of small polyps, the inflammatory response continues to increase while the
number of polyps remain constant which indicates that the inflammatory response after 12
weeks could largely be driven by polyp size. However, it is still unclear whether the
changes in polyp number and size that occurs in this model is a result of the elevated
inflammatory response or vice versa (McClellan, Davis, Steiner, Enos, et al., 2012).

2.9 The Bacteroidetes and Firmicutes
The gut microflora plays a very important role in the immunology, nutrition and pathology
of an organism. A limitation in the methodical techniques and inherent biases involved in
the carrying out culture-based techniques to study gut microbiome had previously limited
our knowledge in better understanding the gut microbiome from the point of view of not
only characterizing it as whole but also elucidating the mechanisms it can affect that may
lead to various disease outcomes in living systems. New methodologies have now been
developed to study the diversity of the gut microbial community, which was formerly
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thought to contain merely 400-500 species. The total of 1250 Operational Taxonomic Units
representing the gut bacterial species have been identified by the use of the recently
developed mapping techniques (Mariat et al., 2009). In the context of humans, 80% of the
mapped fecal bacteria contains three major phyla: Bacteroidetes, Firmicutes and
Actinobacteria (Lay et al., 2005). The gut microbiome is a complex ecosystem containing
a dominant population (>109 CFU/g) of anaerobic bacterial species represented by genera
of Bacteroides, Eubacterium, Bifidobacterium, Peptostreptococcus, Ruminococcus,
Clostridium and Propionibacterium, and sub-dominant (< 109 CFU/g) population of
aerobic bacteria pertaining to the Enterobacteriaceae family, especially E. coli, and the
genera Streptococcus,

Enterococcus,

Lactobacillus,

Fusobacterium,

Desulfovibrio and Methanobrevibacter (Harmsen, Raangs, He, Degener, & Welling,
2002).

The establishment and diversification of the gut microbiome is a gradual process
that is required for proper development and overall health. Once the gut microbiome
manifests itself completely, its stays constant during the life of a healthy individual (Franks
et al., 1998) which explains the fact that an alteration in one or more of the resident
microbial populations lead to pathological conditions.
The Bacteroidetes phylum is comprised of Gram-negative anaerobic and aerobic
bacterial species. Some studies link the absence or reduction of, or delayed colonization of
the gut by the phylum Bacteroidetes to be associated with a weakened immune system in
humans. For example, a delayed postnatal colonization of Bacteroidetes population has
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been associated with development of allergies in children born by Caesarian section (S.
Watanabe et al., 2003).
The Firmicutes represent the phylum mostly containing Gram-positive bacterial
species. The phylum contains both aerobic and anaerobic bacterial species.
Many Firmicutes are capable of producing endospores which help them survive
desiccation and extreme conditions. Their capability to survive extreme conditions may be
one reason that these bacteria are found in high numbers in the gut under pathological and
inflammatory conditions. Comparisons of gut microbiota of lean and obese mice and lean
and obese human individuals revealed that the Bacteroidetes significantly decrease while
the Firmicutes significantly increase with obesity (Guo et al., 2008).

2.10 16S rRNA gene profiling and sequencing
The gut microflora plays a very important role in the immunology, nutrition and pathology
of an organism. A limitation in the methodical techniques and inherent biases involved in
the carrying out culture-based techniques to study gut microbiome had previously limited
our knowledge in better understanding the gut microbiome from the point of view of not
only characterizing it as whole but also elucidating the mechanisms it can affect that may
lead to various disease outcomes in living systems. New methodologies have now been
developed to study the diversity of the gut microbial community, which was formerly
thought to contain merely 400-500 species. The total of 1250 Operational Taxonomic Units
representing the gut bacterial species have been identified by the use of the recently
developed mapping techniques (Mariat, et al., 2009). In the context of humans, 80% of the
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mapped fecal bacteria contains three major phyla: Bacteroidetes, Firmicutes and
Actinobacteria (Lay, et al., 2005). One of the most widely used of these methods is the 16S
rRNA method. The 16S rRNA gene method is one of the earliest and most widely used
methods used for phylogenetic, taxonomic and bioinformatics analyses. It targets the 16S
rRNA bacterial genes to know diversity or similarities in biological samples. The 16S
rRNA gene provides many advantages in microbiome analyses including its universal
distribution in bacterial species, relative stability in evolution and ideal size (1500 bp).
Consisting of both constant and variable regions, the 16S gene is easy to amplify used
broad-range primers used against regions flanking its variable regions (Sankar, Lagier,
Pontarotti, Raoult, & Fournier, 2015).

2.11 Statistical Power of the study
The microbiome analysis in our study was done using the fecal samples from experimental
mice. A 16S rRNA gene sequencing technique was used to study the gut microbial
populations in the animals. The sample size for the study is 4. Some of the previous studies
that have been directed towards similar microbial analyses have used similar samples sizes.
Russell et al (2012) (Russell et al., 2012) used n = 3-5 to study changes in the gut microbial
communities in C57BL/6 mice following antibiotic treatment at neonatal and adult stages
of life. The results showed significant reductions in the overall bacterial diversity and phyla
abundance in antibiotic-treated mice as compared to control mice (p value<0.05). Oh et al
(2016) (Oh et al., 2016) used a sample size of 5 mice per group in order to show significant
differences in bacterial load and diminished rDNA in antibiotic-treated mouse fecal
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samples as compared to their control counterparts. Similar studies have used n = 4-6 mice
per group in order to show Significant (p value<0.01) changes in gut microbial constituents
as a result of administration of the antibiotic enrofloxacin with an increase in type-2
cytokines has been shown in a study that used 4 to 6 (n) mice per group (Strzepa et al.,
2016).
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CHAPTER 3

GUT MICROBIOME PROFILE DURING INITIATION AND PROGRESSION OF
TUMORIGENESIS IN APCMIN/+ MOUSE 1

Kamaljeet Kaur, Arpit Saxena, Alexander Sougiannis, Sarah Depaepe, Raja Fayad,
Anindya Chanda and James Carson. To be submitted.
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3.1 Abstract
An altered gut microbiome can cause inflammation ranging from acute bouts to
chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial
lining that, in turn, leads to more and more inflammatory processes taking place inside the
gut microenvironment. However, there are no studies that study the gut microbiome with
respect to gut inflammation and tumorigenesis in an age/time- dependent manner. Four
weeks old male ApcMin/+ and C57BL/6 (WT) mice were obtained from the Jackson
Laboratories and bred and housed at the Animal Resource Facility at University of South
Carolina. Food (Purina chow) and drinking water was available to the mice ad libidum
under a 12:12 hour light-dark cycle and a low-stress environment (22oC, 50% humidity
and low noise). All animal care followed institutional guidelines under a protocol approved
by the Institutional Animal Care and Use Committee at the University of South Carolina.
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in
stools as a basis for calculating clinical scores (Saxena, et al., 2012). Mice were sacrificed
at 8, 12 and 16 weeks. Bacterial 16S rRNA gene amplification and sequencing were
performed using Polymerase Chain Reaction (PCR) amplification of the V4 region of the
bacterial 16 S rRNA gene. The clinical scores increased with tumor progression in the
ApcMin/+ mice and were significant as compared to the WT mice for which the score
remained 0 for the course of the study. The Bacteroidetes and Firmicutes were found to be
the two dominant phyla in the WT and ApcMin/+ gut which remained so at all three
experimental time points of the study. However, their overall percentages change with
antibiotic treatment where Firmicutes phyla dominated with the treatment. It could be
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concluded from the study that the Firmicutes phyla of bacteria may play a role during the
initiation of tumorigenesis.
Keywords: Microbiome, Inflammation, Bacteroidetes, Firmicutes

3.2 Introduction

The gut microbiome is an integral and an important symbiotic system present in the
gut, which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal
tract throughout its length. The gut bacteria itself comprises a major percentage of the total
gut microbiome, where its numbers are in trillions. While the stomach and duodenum
contain about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the
jejunum and ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria
(Cresci & Bawden, 2015). The microbiome acts advantageous for the gut such that it
regulates gut epithelial and endocrine cellular structure (Uribe, et al., 1994). Previously,
many studies have demonstrated an alteration in gut microbiota to be linked to a variety of
conditions including diabetes, arthritis, colitis and cancer and even immune system.
Conditions such as Crohn’s disease and obesity have implicated gut bacterial dysbiosis in
pathogenesis (Chan, et al., 2015; Mai, et al., 2007). It was not clear if the bacterial dysbiosis
is a cause or consequence of the disease until recently when it was shown that alterations
in gut microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). An altered
gut microbiome can cause inflammation ranging from acute bouts to chronically inflamed
gut. An altered microbiome, which shifts from symbiotic to a more inflammation-inducing
phenotype, leads to a vicious cycle of erosion of the gut epithelial lining that, in turn, leads
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to more and more inflammatory processes taking place inside the gut microenvironment
(Saxena, et al., 2012; Zhang, et al., 2015). A need to address and characterize host-microbe
relations has been emphasized in recent years in order to elucidate the processes and factors
involved in the relationship between the gut microbiome and inflammation and related
tumorigenesis. The intestinal epithelial lining has a strong relationship to the gut bacteria.
The bacterial flora of the intestine helps in digesting the food (especially carbohydrates)
that cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells
metabolize the short-chain fatty acids that result from the bacterial fermentation of the
undigested carbohydrates and use them as an energy source (Abreu, 2010). There are no
studies that study the gut microbiome with respect to gut inflammation and tumorigenesis
in an age/time- dependent manner. How the microbiota changes in the first place and then
a subsequent change occurs in the inflammatory pathways during spontaneous
tumorigenesis is a question that the present study aimed at answering via studying different
stages of tumorigenesis.

3.3 Methods

Experimental animals and groups
Four weeks old male ApcMin/+ and C57BL/6 (WT) mice were obtained from the Jackson
Laboratories and bred and housed at the Animal Resource Facility at University of South
Carolina. Food (Purina chow) and assigned to each of the following six groups with four
mice each (n=4): WT- 8, 12 and 16 weeks; and ApcMin/+- 8, 12 and 16 weeks. Food (Purina
chow) and drinking water was available to the mice ad libidum under a 12:12 hour light-
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dark cycle and a low-stress environment (22oC, 50% humidity and low noise). All animal
care followed institutional guidelines under a protocol approved by the Institutional Animal
Care and Use Committee at the University of South Carolina.

Clinical score
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in
stools. Clinical score was measured for each mouse twice during each week of the study
based on our earlier published criteria (Saxena et al., 2012). Mice were sacrificed after the
last clinical score measurement. Cumulative clinical scores for each mouse equaled a
maximum score of 12, which was based on weight loss measurement, diarrhea and fecal
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the
three quantitative parameters. Score for the weight loss was based on the following
published scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–15% weight
loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea was as
follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do not adhere to
the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the stools was
determined by using hemoccult kit (BECKMAN COULTER), which is a hydrogen
peroxide-based kit that forms a visible blue colored complex with blood. The followings
were the score rates for the fecal hemoccult: 0 = no blood, 2 = positive hemoccult, 4 =
gross bleeding. The total clinical score was the summation of the individual score of weight
loss, diarrhea and fecal hemoccult. The maximum score a mouse could get was 12.
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Collection of tissues
Mice (n=4 for each age group and genotype) were sacrificed at 8, 12 and 16 weeks by
cervical dislocation. Blood was collected before sacrifice through retro-orbital puncture,
centrifuged at 10,000 rpm for 15 minutes and serum was isolated and stored at -20°C. Small
intestine and colon were excised and flushed clean with PBS. 2 mm2 colon tissue sections
were fixed in 10% formalin and were replaced with 70% ethanol after 24 hours, followed
by paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2
intestine and colon tissue sections were incubated in RPMI medium at 37°C for 24 hours
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant was obtained and
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of the tissues
were stored at -80oC for further usage. Fecal samples were snap frozen at the time of
sacrifice for microbiome analysis.

Microbiome analysis
At sacrifice, fecal samples were obtained from the experimental mice to perform bacterial
(luminal) microbiome analysis (n=3). Bacterial n16S rRNA gene amplification and
sequencing were performed at the Alkek Center for Metagenomics and Microbiome
Research, Department of Molecular Virology and Microbiology, Baylor College of
Medicine (Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4
region of the bacterial 16 S rRNA gene was performed using the Illumnia Miseq sequencer.
The consensus sequences obtained from the analysis were mapped into Operational
Taxonomic Units (OTUs). Alpha- and beta-diversity values were obtained based on the
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OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity
Index (richness and evenness) were used to obtain the alpha diversity values. Weighted
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance)
were performed to obtain the beta-diversity values for the experimental samples (He et al.,
2016). Kruskal Wallis and Mann Whitney statistical analyses were performed to calculate
significance in diversity and relative abundance respectively, by comparing different
treatments and disease stages. A p value of less than 0.05 was considered significant.
Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the
significance of differences obtained between different experimental treatment conditions
and between the experimental mouse strains used in the study. A p<0.05 were considered
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS,
Chicago, IL). The sample size (n) was kept as 4 for the study.

3.4 Results

Clinical score increases with tumor progression in ApcMin/+ mice
Clinical score which is a culmination of diarrhea, weight loss and fecal hemoccult was
plotted against the age of mice (n=4) at 8, 12 and 16 weeks (figure 3.1). Clinical score was
found to increase with age of ApcMin/+ mice. ApcMin/+ mice at 6, 8, 10, 12, 14, and 16 showed
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a significantly higher clinical score when compared to ApcMin/+ mice at 5 weeks (#p<0.03,
dotted line) (figure 3.1 A, B and C). ApcMin/+ mice of 8, 10, 12, 14 and 16 weeks of age
showed a significantly higher clinical score when compared to ApcMin/+ mice at 6 weeks of
age (*p<0.05). ApcMin/+ mice of 10, 12, 14 and 16 weeks of age showed a significantly
higher clinical score when compared to ApcMin/+ mice at 8 weeks of age (**p<0.01). No
significant difference was found between the clinical score of ApcMin/+ mice at age 10, 12,
14 and 16 weeks (figure 3.1 A, B and C).

Microbiome profile during tumor initiation
The bacterial microbiome profiles of the experimental animals were studied without
antibiotic treatment to establish the control profiles of the gut microbial community. The
Bacteroidetes and Firmicutes were the two main phyla among others that were profiled
through the 16S rRNA sequencing. The bacterial population including proteobacteria,
firmicutes and bacteroidetes was found to fluctuate with age and genotype. The percentage
of Proteobacteria was found be significantly higher in ApcMin/+ mice at 8 weeks (16.9%)
when compared to WT mice (3.7%) and ApcMin/+ mice at 12 (3.8%) and 16 weeks (5.1%).
No significant difference was observed in the proteobacterial population between the
ApcMin/+ mice and WT mice at 12 and 16 weeks (figure 3.2 A). Percentage of firmicutes
bacteria in the feces of the ApcMin/+ mice at 8 weeks (48.8%) was significantly higher than
at 12 weeks (33.2%) and 16 weeks (21.2%). Percentage of firmicutes bacteria was found
to be significantly higher at 8, 12 and 16 weeks when compared to their WT counterparts
(12.0%). Percentage of firmicutes population in ApcMin/+ mice at 16 weeks (21.2%) was
found be significantly lower than the ApcMin/+ mice at 12 weeks (33.2%) (figure 3.2 B).
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Bacteroidetes showed an opposite trend in bacterial population when compared with
firmicutes and proteobacteria. Percentage of bacteroidetes in ApcMin/+ mice at 8 weeks
(30.6%) was found be significantly lower than both WT (83.6%) and ApcMin/+ mice at 12
(61.8%) and 16 weeks (71.8%) of age. ApcMin/+ mice at 12 weeks of age showed a
significantly lower bacteroidetes population when compared to WT mice. No significant
difference was observed in the bacteroidetes population of ApcMin/+ mice at 16 weeks and
WT mice (figure 3.2 C).

3.5 Discussion

An alteration in gut microbiome has been previously demonstrated to be linked to a variety
of conditions including diabetes, arthritis, colitis and cancer and even immune system.
Conditions such as Crohn’s disease and obesity have implicated gut bacterial dysbiosis in
pathogenesis (Chan, et al., 2015; Mai, et al., 2007). It was not clear if the bacterial dysbiosis
is a cause or consequence of the disease until recently when it was shown that alterations
in gut microbiome precede polyposis in the ApcMin/+ mouse (Son, et al., 2015). Our present
study aimed at characterizing the bacterial populations that can be regarded as significant
in the process of tumorigenesis. The Proteobacteria and the Firmicutes phylum were
significantly higher in ApcMin/+ mouse during initial stages of tumorigenesis as compared
to WT mice indicating that the phyla can be a precursor to and important during the initial
stages of tumorigenesis. The study by Son et al (Son, et al., 2015) demonstrated a higher
Bacteroidetes population in this regard. A reason that can be cited for this discrepancy in
observations is that the mice used were at initial stages of tumorigenesis and it can well be
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possible that some of the ApcMin/+ may not have even developed polyps at the age of
euthanization (8 weeks). The observations however, support the higher percentages of the
Bacteroidetes phylum that was observed in the WT mice at the age of 8 weeks in our study.
Moreover, the observation that the ApcMin/+ mice showing a clinical score at 5 weeks which
continued to increase till 8 weeks, while the WT mice exhibited no clinical signs of disease,
makes Firmicutes the likely bacterial phylum that can set the stage for tumorigenesis rather
than the Bacteroidetes that are abundant in the WT mice at this age but do not lead to any
clinical score.
The percentage of Proteobacteria and the Firmicutes phylum decreased
significantly at 12 and 16 weeks. Percentage of Proteobacteria phylum in ApcMin/+ mouse
becomes almost similar to the WT mice. However, the percentage of Firmicutes showed a
similar pattern but remains significantly higher than WT mice. Both of these phylum
showed a decrease with increase in tumorigenesis. The restoration of these phylum levels
to almost those of the WT mice may be seen as a defense mechanism of the digestive tract
under the absence of any external manipulation of the gut microbiome. Concomitantly, we
also observed an increase in the percentage of Bacteroidetes with age further strengthening
the idea that higher percentage of Proteobacteria and Firmicutes and lower percentage of
Bacteroidetes could set a stage for tumorigenesis and then body defense mechanism tries
to restore the gut microbiome (figure 3.2). However, clinical scores for the tumor-bearing
mice continued to increase until 16 weeks (figure 3.1), an indication that levels of
Proteobacteria, Firmicutes and Bacteroidetes may not correlate with disease prognosis
once the process of tumorigenesis starts. This finding is also corroborated by the
observation of the species richness values that were not significantly different between
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experimental time points within the two animal groups. However, the overall diversity
between the ApcMin/+ and WT mice was significant whether species abundance is taken into
account or not.
3.6 Conclusion
In conclusion, it can be stated that reduced abundance of the phylum Firmicutes
can be cited as one of the factors that set the conditions for initiation of tumorigenesis in
the mouse gut although the two phyla Firmicutes and Bacteroidetes do not bear any
significant correlation to the clinical scores for the tumor-bearing mice during the
progression of tumorigenesis. With an absence of any external manipulation of the gut
microbiome, the species present in the normal mice may not be similar to that present in
tumor-bearing mice at 8, 12 and 16 weeks of age. However, phylogenetically, the species
members residing in a tumor-bearing gut may significantly be different and diverse from
those residing in a normal gut. A bigger samples size may help elucidate interesting links
between the major gut microbial members and tumorigenesis with respect to phylogenetic
and diversity analyses.
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3.7 Figure Legends

Figure 3.1. Clinical score (A–C) Clinical scores for ApcMin/+plotted for different time
points during the study (n=4). The scores were calculated out of twelve points; four points
for each parameter: weight loss, diarrhea and hemoccult. Two-way repeated measure of
analysis of variance (ANOVA) was used to calculate the significant difference between the
clinical score for ApcMin/+ mice between different time points throughout the length of the
experiment. #p<0.03 ApcMin/+ vs ApcMin/+ 5 weeks, *p<0.05 vs ApcMin/+ at 6 weeks and
**p<0.01 vs ApcMin/+ at 8 weeks .

Figure 3.2. Intestinal microbiome phylum profiles. Relative percentages of the major
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental
mice (n=4): (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage
values represent fractions of depicted bacteria out of the total microbial pool). Two-way
analysis of variance (ANOVA) was used to calculate the significant difference between the
percentage of bacteria in ApcMin/+ control and WT control mice at age 8, 12 and 16 weeks.
*p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs 16 weeks) and #p<0.01
Apc-min vs WT.
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Figure 3.1. Clinical score (A–C) Clinical scores for ApcMin/+ plotted for different time
points during the study (n=4). The scores were calculated out of twelve points; four points
for each parameter: weight loss, diarrhea and hemoccult. Two-way repeated measure of
analysis of variance (ANOVA) was used to calculate the significant difference between the
clinical score for ApcMin/+ mice between different time points throughout the length of the
experiment. #p<0.03 ApcMin/+ vs ApcMin/+ 5 weeks, *p<0.05 vs ApcMin/+ at 6 weeks and
**p<0.01 vs ApcMin/+ at 8 weeks.
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Figure 3.2. Intestinal microbiome phylum profiles. Relative percentages of the major
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental
mice (n=4): (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage
values represent fractions of depicted bacteria out of the total microbial pool). Two-way
analysis of variance (ANOVA) was used to calculate the significant difference between the
percentage of bacteria in ApcMin/+ control and WT control mice at age 8, 12 and 16 weeks.
*p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs 16 weeks) and #p<0.01
Apc-min vs WT.
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CHAPTER 4

EFFECT OF GUT MICROBIOME MANIPULATION ON GUT HEALTH AND
TUMORIGENESIS IN APCMIN/+ MOUSE 2

Kamaljeet Kaur, Arpit Saxena, Sarah Depeape, Alexander Chumanevich, Raja Fayad,
Anindya Chanda and James Carson. To be submitted.
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4.1 Abstract
The mucus layer acts as a site of residence for the gut microbiota. The metabolites
produced by the microbes influence the differentiation and function of the epithelial and
immune cells in the intestinal mucosa. The gut microbiota can regulate mucin gene
expression and mucus production. Our recent study suggested a reduction in the secretory
mucin profile to be associated with an inflammatory phenotype of the gut. 4 weeks old
ApcMin/+ and C57BL/6 (WT) mice were housed at the Animal Resource Facility, University
of South Carolina with access to food and water ad libidum. The ApcMin/+ and C56BL/6
mice were assigned to the following groups: WT-Control (no antibiotic)-8 weeks, WTAntibiotic (ABT)-8 weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16
weeks, WT-ABT-16 weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+Control-12 weeks, ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT16 weeks. An antibiotic mixture containing Vancomycin, Neomycin and Ampicillin (each
1 mg/mL) was administered to experimental mice through drinking water starting at the
5th, 10th and 14th weeks of age for 10 days followed by normal drinking water. Mice were
monitored twice during each week of the study for weight loss, diarrhea and blood in stools
to serve as basis for calculating clinical scores. Small intestine and colon from the animals
was excised, flushed with PBS and tumor number and area were counted using 1% Methyl
Blue stain. Small intestinal samples were stained with Alcian Blue dye solution for
quantifying mucus-containing goblet cells. The clinical scores for the animals increased
with antibiotic treatment except for WT-C mice for which the scores were 0 throughout the
study. The highest clinical scores were exhibited with tumorigenesis as well as microbiome
manipulation. Polyp counts for the ApcMin/+ mice increased with antibiotic treatment. A
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significantly higher percentage of the Firmicutes phylum was observed with microbiome
manipulation. The goblet to epithelial cell ratio was significantly reduced in both ApcMin/+
and WT mice with antibiotic treatment during all three experimental time points. Our
results suggest that Firmicutes within the gut microbiome plays a regulatory role in colonic
epithelial to goblet cell differentiation and tumorigenesis.

Keywords: Microbiome, polyps, tumor, Firmicutes, ApcMin/+

4.2 Introduction

An altered gut microbiome can cause inflammation ranging from acute bouts to
chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial
lining that, in turn, leads to more and more inflammatory processes taking place inside the
gut microenvironment (Saxena, et al., 2012; Zhang, et al., 2015). A need to address and
characterize host-microbe relations has been emphasized in recent years in order to
elucidate the processes and factors involved in the relationship between the gut microbiome
and inflammation and related tumorigenesis. Inflammation is an important route through
which alterations in gut microbiota affect the overall milieu of inflammatory processes
closely associated with the gut. Gut microbiota manipulation through antibiotic treatment
has been shown to cause a decrease in the expression of the Muc2 protein, a major
component of the intestinal mucus layer (Dimmitt, et al., 2010). A thinning of the
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protective mucus layer leads to a direct contact between the gut lining and the gut bacteria
residing in the lumen, thereby triggering innate immune responses and inflammation
(Francino, 2015). The inflammatory response, along with being systemic, also occurs at a
more localized level such as the alterations in gut microbiota leading to increased levels of
pro-inflammatory cytokines such as IL-1β and TNF-α (Vijay-Kumar, et al., 2010). It has
been shown that the mucus layer tends to thickness with increased diversity of the
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans
present in the mucus, making the inter-relationship between the gut bacteria and the mucus
layer really important (Kaur, et al., 2015). Also, the metabolites produced by these
microbes also influence the differentiation and function of the epithelial and immune cells
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et
al., 2015) also suggested that a reduction in the secretory mucin profile is associated with
an inflammatory phenotype of the gut. Both Gram-positive and Gram-negative bacteria are
known to enhance the intestinal mucin expression (Dohrman, et al., 1998). The regulation
of the mucin gene expression as well as mucus production have been shown to be two
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008).
Gut microbiota manipulation through antibiotic treatment has been shown to cause a
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus
layer (Wlodarska, et al., 2011). A thinning of the protective mucus layer leads to a direct
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering
innate immune responses and inflammation (Francino, 2015).
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Studies that work at elucidating the role of gut microbes in disease models, have
been limited, especially due to the fact that most of the important gut bacteria are difficult
to grow in a laboratory setting making them unavailable for studying unless mammalian
models are used. However, there are evidences that the manipulation of the gut microbiome
through diet modulations, can alter the disease conditions such as those in Crohn’s disease
and Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse
model for studying gut diseases and their association with microbiota often report
significant changes in microbiome profiles of the large intestine, but also report that
differences in the polyps is only significant in the small intestine (Mai, et al., 2007) The
detrimental effects are also brought about via loss of certain colonizing bacterial species
that are dependent on other colonizers for processes such as nutritional interactions and
removal of secondary metabolites and toxic waste products (Belenguer, et al., 2006), or
through loss of useful co-evolved processes brought about by the host-microbial codependence (Atarashi & Honda, 2011; Ferreira, et al., 2011). There are no studies that
study the gut microbiome with respect to gut inflammation and tumorigenesis in an
age/time- dependent manner.

4.3 Materials and methods

Experimental animals and groups, Collection of tissues
4 weeks old ApcMin/+ and C57BL/6 (WT) mice were obtained from Jackson Laboratories
and bred in-house at the Animal Resource Facility, University of South Carolina. Food
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(Purina chow) and drinking water was available to the mice ad libidum under a 12:12 hour
light-dark cycle and a low-stress environment (22oC, 50% humidity and low noise). The
ApcMin/+ and C56BL/6 mice were assigned to the following twelve groups with 4 mice in
each group (n=4): WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 weeks,
WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 weeks,
ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, ApcMin/+ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. Experimental
animals from aim 1 were used for aim 2 as control animals. All animal care followed
institutional guidelines under a protocol approved by the Institutional Animal Care and Use
Committee at the University of South Carolina.

Collection of tissues
Mice (n=4 separate for each age group, genotype and treatment group) were sacrificed at
8, 12 and 16 weeks by cervical dislocation. The control mice for the present experiment
were the same as used under aim1. Blood was collected before sacrifice through retroorbital puncture, centrifuged at 10,000 rpm for 15 minutes and serum was isolated and
stored at -20°C. Small intestine and colon were excised and flushed clean with PBS. 2 mm2
colon tissue sections were fixed in 10% formalin and were replaced with 70% ethanol after
24 hours, followed by paraffin embedding and sectioning to obtain 5 µm thin sections on
glass slides. 2 mm2 intestine and colon tissue sections were incubated in RPMI medium at
37°C for 24 hours followed by centrifugation at 2500 rpm for 15 minutes. Supernatant was
obtained and stored at -20°C for tissue-secreted cytokine expression analyses. The rest of
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the tissues were stored at -80oC for further usage. Fecal samples were snap frozen at the
time of sacrifice for microbiome analysis.

Microbiome analysis
At sacrifice, fecal samples were obtained from the experimental mice to perform bacterial
(luminal) microbiome analysis (n=3). Bacterial 16S rRNA gene amplification and
sequencing were performed at the Alkek Center for Metagenomics and Microbiome
Research, Department of Molecular Virology and Microbiology, Baylor College of
Medicine (Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4
region of the bacterial 16S rRNA gene was performed using the Illumnia Miseq sequencer.
The consensus sequences obtained from the analysis were mapped into Operational
Taxonomic Units (OTUs). Alpha- and beta-diversity values were obtained based on the
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity
Index (richness and evenness) were used to obtain the alpha diversity values. Weighted
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance)
were performed to obtain the beta-diversity values for the experimental samples (He, et al.,
2016). Kruskal Wallis and Mann Whitney statistical analyses were performed to calculate
significance in diversity and relative abundance respectively, by comparing different
treatments and disease stages. A p value of less than 0.05 was considered significant.
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Antibiotic treatment
An antibiotic mixture containing Vancomycin, Neomycin and Streptomycin (each 1
mg/mL) was administered to experimental mice belonging to the antibiotic treatment
groups. While neomycin and streptomycin act against Gram-negative bacteria,
vancomycin is used against Gram-positive bacteria. The antibiotics mixture was
administered to the mice through drinking water starting at the 5th, 10th and 14th weeks of
age for 10 days followed by normal drinking water.

Clinical score
Mice were monitored throughout the course of study for weight loss, diarrhea and blood in
stools. Clinical score was measured for each mouse twice during each week of the study.
Mice were sacrificed after the last clinical score measurement. Cumulative clinical scores
for each mouse equaled a maximum score of 12, which was based on weight loss
measurement, diarrhea and fecal hemoccult (kit, BECKMAN COULTER) with a
maximum score of 4 within each of the three quantitative parameters. Score for the weight
loss was based on the following published scale where 0 = 0–5% weight loss; 1 = 6–10%
weight loss; 2 = 11–15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss.
Scoring of diarrhea was as follows: 0 = well-formed pellets, 2 = pasty and semi-formed
stools that do not adhere to the anus, 4 = liquid stools that adhere to the anus. Detection of
blood in the stools was determined by using hemoccult kit (BECKMAN COULTER),
which is a hydrogen peroxide-based kit that forms a visible blue colored complex with
blood. The followings were the score rates for the fecal hemoccult: 0 = no blood, 2 =

56

positive hemoccult, 4 = gross bleeding. The total clinical score was the summation of the
individual score of weight loss, diarrhea and fecal hemoccult. The maximum score a mouse
could get was 12.
Polyp count
Small intestine and colon from the experimental animals were excised and flushed with
PBS. Tumor number and area was counted using 1% Methyl Blue stain under the light
microscope for all mice in different groups and significant difference was calculated.
Tumor number and/or area were also correlated with the manipulation of the microbiome.
Goblet to epithelial cell ratio
Small intestinal samples (0.5 cm) were embedded in paraffin wax and sectioned using a
microtome into 10 µm sections obtained on glass slides. Standard deparaffinization
procedure was followed using xylene and gradations of ethanol for the small intestinal
sections. Alcian Blue dye solution for staining mucus-containing goblet cells was prepared
by dissolving the dye powder (8GX) at 1% concentration in 3% acetic acid solution and
setting the pH at 2.5. Nuclear Fast Red solution for staining the epithelial cells of the
mucosa were prepared at a final concentration of 0.1% dissolved in 5% aluminum sulfate
solution. Tissues were firstly stained with Alcian Blue and then counterstained with
Nuclear Fast Red solution. Goblet to epithelial cell ratio was calculated per crypt with ten
crypts per section and five sections per group.
Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the
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significance of differences obtained between different experimental treatment conditions
and between the experimental mouse strains used in the study. A p<0.05 were considered
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS,
Chicago, IL). The sample size was kept as 4 for the study.

4.4 Results
Clinical scores
Clinical scores were recorded twice per week during the course of study for all
experimental animals to know the disease prognosis and health. Mice sacrificed at 8 weeks
of age (figure 4.1 A): ApcMin/+ mice ABT group showed significantly higher clinical score
than both ApcMin/+ control and WT-ABT group at 6 weeks. ApcMin/+ mice at 8 weeks
showed significantly higher clinical score than 6 weeks and WT-ABT group. Lastly,
ApcMin/+ mice ABT group showed significantly higher clinical score than WT-ABT mice
at 8 weeks.
Mice sacrificed at 12 weeks of age (figure 4.1 B): ApcMin/+ mice at 6 and 8 weeks
of age showed a significantly lower clinical score than WT-ABT group. ApcMin/+ mice at
8, 10 and 12 weeks of age showed a significantly higher clinical when compared to ApcMin/+
mice at 6 weeks of age. ApcMin/+ mice at 10 and 12 weeks of age showed a significantly
higher clinical score than ApcMin/+ mice at 8 weeks of age. ApcMin/+ mice ABT group at 6
and 8 weeks of age showed a significantly higher clinical score than ApcMin/+ mice at the
same age respectively. ApcMin/+ mice ABT group at 12 weeks of age showed a significantly
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higher clinical score than WT-ABT group. No significant difference was observed between
other treatment groups.
Mice sacrificed at 16 weeks of age (figure 4.1 C): ApcMin/+ mice at 6 weeks of age
showed a significantly lower clinical score than WT-ABT group. ApcMin/+ mice at 8, 10,
12, 14 and 16 weeks of age showed a significantly higher clinical score than ApcMin/+ mice
at 6 weeks of age. ApcMin/+ mice at 16 weeks of age showed a significantly higher clinical
score than ApcMin/+ ABT mice at 8 weeks of age. ApcMin/+ ABT group at 6, 8, 12 and 16
weeks of age showed a significantly higher clinical score than ApcMin/+ mice at the same
age respectively. ApcMin/+ mice ABT group at 16 weeks of age showed a significantly
higher clinical score than ApcMin/+ ABT group at 6, 8, 12 and 14 weeks of age.

Polyp count
The total polyp count in ApcMin/+ ABT and ApcMin/+ control mice group at 12 and 16 weeks
of age was significantly higher when compared to the mice within the same group at 8
weeks. ApcMin/+ ABT and ApcMin/+ control at 16 weeks of age showed a significant increase
in the polyp count when compared to the mice belonging to the same group at 12 weeks of
age. Only ApcMin/+ ABT mice at 16 weeks of age showing a significantly higher polyp
count when compared to the ApcMin/+ control at the same age (figure 4.2A). No significant
difference was observed in the polyp count of ApcMin/+ ABT and ApcMin/+ control at 8 and
12 weeks of age.
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Polyp count (<1 mm2)
No significant difference was observed between the ABT-treated and control ApcMin/+ mice
for the number of intestinal polyps less than 1 mm2 area, at 8, 12 and 16 weeks. Also no
significance was observed within the ApcMin/+ ABT and ApcMin/+ control group at 8, 12 and
16 weeks of age (figure 4.2B).

Polyp count (>1 mm2)
Intestinal polyps measuring more than 1 mm2 in area were significantly increased in
ApcMin/+ ABT and ApcMin/+ control mice group at 12 and 16 weeks of age was significantly
higher when compared to the mice within the same group at 8 weeks. ApcMin/+ ABT and
ApcMin/+ control at 16 weeks of age showed a significant increase in the polyp count (>1
mm2) when compared to the mice belonging to the same group at 12 weeks of age. Only
ApcMin/+ ABT mice at 16 weeks of age showed a significantly higher polyp count (>1 mm2)
when compared to the ApcMin/+ control at the same age (figure 4.2B). No significant
difference was observed in the polyp count of ApcMin/+ ABT and ApcMin/+ control at 8 and
12 weeks of age.

Goblet cells
Goblet to epithelial cell ratio provide an indirect measure in order to quantify mucus
production in the small intestine which is closely related to the gut resident bacterial
community although the mechanisms for the same are not known. The goblet to epithelial
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cell ratio decreased significantly at 12 and 16 weeks of age and increased significantly at
12 and 16 weeks of age in WT control group and WT ABT group respectively when
compared within the respective group at 8 weeks of age. Goblet to epithelial cell ratio was
found to be significantly higher in WT control group at 8, 12 and 16 weeks when compared
to WT ABT group at the same age (figure 4.3 A and B). No significant difference was
observed in the goblet to epithelial cell ratio with other group or with age.
The goblet to epithelial cell ratio decreased significantly at 12 and 16 weeks of age
in ApcMin/+-Control and ApcMin/+-ABT group when compared within the respective group
at 8 weeks of age. The ratio was also found to be significantly lower in ApcMin/+ control
group at 16 weeks of age when compared with 12 weeks of age within the same group.
Goblet to epithelial cell ratio was found to be significantly higher in ApcMin/+ control group
at 8, 12 and 16 weeks when compared to ApcMin/+ ABT group at the same age (figure 4.3
A and C). No significant difference was observed in the goblet to epithelial cell ratio with
other group or within group with age.

The bacterial population including proteobacteria, firmicutes and bacteroidetes was found
to fluctuate with age, genotype and antibiotic treatment. The percentage of Proteobacteria
was found be significantly higher in ApcMin/+ control mice at 8 weeks when compared to
WT control mice and ApcMin/+ control mice at 12 and 16 weeks. No significant difference
was observed in the proteobacterial population between the ApcMin/+ and WT control mice
at 12 and 16 weeks. Percentage of proteobacteria in ApcMin/+ control mice at 8 weeks was
found to be significantly higher when compared to ApcMin/+ ABT treated mice at the same
age. However, at 16 weeks the percentage of proteobacteria in ApcMin/+ control mice were
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found to be significantly lower than ApcMin/+ ABT treated mice at the same age. No
significance in the proteobacterial population was observed between other groups with
change in either treatment, age or genotype. The percentage of firmicutes bacteria in WT
ABT treated mice, ApcMin/+ control mice and ApcMin/+ ABT treated mice at age 8, 12 and
16 weeks was found to be significantly higher than the WT control mice. The percentage
of firmicutes bacteria in WT ABT treated and ApcMin/+ ABT treated mice at age 8, 12 and
16 weeks was significantly higher than the ApcMin/+ control mice at the respective age.
Percentage of firmicutes bacteria in the feces of the ApcMin/+ mice at 8 weeks was
significantly higher than at 12 weeks and 16 weeks. Percentage of firmicutes bacteria was
found to be significantly higher at 8, 12 and 16 weeks when compared to their WT
counterparts. Percentage of firmicutes population in ApcMin/+ mice at 16 weeks was found
be significantly lower than the ApcMin/+ mice at 12 weeks. No significant difference was
observed in the firmicutes population of WT ABT treated and ApcMin/+ ABT treated mice
with age. The percentage of bacteroidetes bacteria in WT ABT treated mice, ApcMin/+
control mice and ApcMin/+ ABT treated mice at age 8, 12 and 16 weeks was found to be
significantly lower than the WT control mice. Percentage of bacteroidetes in ApcMin/+ mice
at 8 weeks was found be significantly lower than both WT and ApcMin/+ mice at 12 and 16
weeks of age. No significant difference was observed in the bacteroidetes population at 16
weeks between ApcMin/+ mice and WT mice. The percentage of bacteroidetes bacteria in
WT ABT treated and ApcMin/+ ABT treated mice at age 8, 12 and 16 weeks was found to
be significantly lower than the ApcMin/+ control mice. No significant difference was
observed in the bacteroidetes population of WT ABT treated and ApcMin/+ ABT treated
mice with age.

62

4.5 Discussion

Our study aimed at following the processes of tumorigenesis and its resulting
disease prognosis and intestinal mucus secretion phenotype upon microbial manipulation
at three different time points representing different stages of tumorigenesis. The antibiotic
treatment lead to an significant increase in the percentage of the Firmicutes population. In
our previous study, the phylum was observed to be present abundantly during the initial
stages of tumorigenesis while decreasing in abundance gradually from 12 weeks to 16
weeks. The phylum showed a similar trend in the control groups while continuing to remain
high even at 12 (tumor development) and 16 weeks (later stages of tumorigenesis) of age
with antibiotic treatment. Our data may corroborate other studies that demonstrated that
even when the antibiotic treatment is stopped, and some resilient bacteria repopulate the
gut, the final state is never a complete replacement of the initial state (Francino, 2015). Our
clinical score continued to remain high at 12 and 16 weeks for the ApcMin/+ with and without
antibiotic treatment and for WT mice with antibiotic treatment. The observation that after
8 weeks, the clinical scores of antibiotic treated ApcMin/+ were not significantly different
from those of the control ApcMin/+ mice indicates towards the insult incurred by the process
of tumorigenesis in the intestinal mucosa. Thus, the physical erosion of the mucosa and the
inflammatory insult by the process of tumorigenesis are not additive during tumorigenic
conditions. However, the antibiotic treatment can lead to an increase in the numbers of
polyps. Moreover, the clinical scores did not correlate to the three time points of antibiotic
administration to the mice, indicating that neither the timing of antibiotic administration
nor the levels of the Firmicutes may have any effect on the disease prognosis. This is not
however the case with the WT phenotype, where antibiotic treatment did produce a clinical
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score even without tumorigenesis during 8, 12 and 16 weeks as compared to the WT mice
without treatment. This indicates towards a more physical effect of microbiome
manipulation on the gut that may lead to the same clinical symptoms that are present with
processes of inflammation and tumorigenesis.
While the external manipulation of the gut microbiome may have physical impacts,
it surely effects the physiology of the intestine as well, as can be seen from the data on the
polyp numbers of the ApcMin/+ mice. While the manipulation of gut microbiome
significantly increased the small intestinal total polyp counts at 16 weeks, the numbers
were not significantly increased between antibiotic and control groups of 8 and 12 weeks.
The antibiotic treatment also significantly increased the polyp numbers at 16 weeks as
compared to those at 12 weeks with antibiotic treatment. The effects of the gut microbiome
manipulation followed a similar trend in case of polyps that measured more than 1 mm in
diameter, while had no significant effect on polyps less than 1 mm diameter. The effects
of gut microbiome manipulation were more pronounced at 16 weeks of age as, the polyp
numbers at 12 weeks with or without antibiotics were significantly increased as compared
to those at 8 weeks with or without antibiotics, there was no significant difference between
the polyp numbers at 12 weeks with and without antibiotics. Interestingly, the manipulation
of the gut microbiome could significantly increase the polyp numbers from 12 to 16 weeks
in the ApcMin/+ mice, there was no significant difference between the polyp numbers at 12
and 16 weeks without antibiotics - a usual characteristic of tumorigenesis in the ApcMin/+
without any treatment, where the polyps only increase in their size and not numbers from
12 weeks to later stages of tumorigenesis (McClellan, Davis, Steiner, Enos, et al., 2012).
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The manipulation of the gut microbiome through antibiotics also significantly
decreased the mucus-producing goblet cell numbers (measured by goblet to epithelial cell
ratio) at all three time points of the present study. While the effect was significant only
between antibiotic treatment and control within the ApcMin/+ and WT mice at 8 weeks, the
microbial manipulation could lower the goblet to epithelial cell ratio in the ApcMin/+ mice
as compared to the WT mice. This may again reflect the additive effects of inflammation,
genetic susceptibility to polyp generation and the physical intestinal insult by the antibiotic
treatment – an effect that was not observed in case of the WT mice.

4.6 Conclusion

It can be concluded that alterations in the gut microbiome community through antibiotic
treatment can render the gut susceptible to an altered re-establishment of microbial
community. The effects of the microbiome manipulation protocol are more obvious on the
total number of polyp numbers in the gut and the on the goblet to epithelial cell ratios in
the intestinal. While under no external treatment, an ApcMin/+ may exhibit only an increase
in polyp size during progression of tumorigenesis towards its later stages, the effect of an
externally manipulated ApcMin/+ microbiome may result in an increase is both polyp
numbers and size as the process of tumorigenesis progress. While the ratio of the intestinal
goblet to epithelia cells is significantly reduced as a result of gut microbial manipulation
in both ApcMin/+ and WT mice, the effect is more obvious in the tumor-bearing mice as
compared to the WT mice.
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4.7 Figure Legends

Figure 4.1. Clinical score with antibiotic treatment. (A–C) Clinical scores for ApcMin/+
mice at different time points (8, 12 and 16 weeks) (n=4 for each group) during the study.
The scores were calculated out of twelve points; four points for each parameter: weight
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA)
was applied to calculate the significant difference between the clinical scores between
different groups. #p<0.03 vs WT-ABT, *p<0.04 vs ApcMin/+ control group at 6 weeks,
$

p<0.05 vs ApcMin/+ within the same age group and φp<0.05 ApcMin/+ ABT at 16 weeks vs

ApcMin/+ ABT at 14, 12, 10, 8 and 6 weeks of age.

Figure 4.2. Tumor Quantification: (A) Graph representing the small intestine polyp
count in ApcMin/+-Control and ApcMin/+-ABT at 8 weeks, 12 weeks and 16 weeks after 1, 2
and 3 cycles of antibiotics respectively. (B) Graph showing polyp number (size < 1mm2)
at 8 weeks, 12 weeks and 16 weeks. (C) Graph showing polyp number (size < 1mm2) at 8
weeks, 12 weeks and 16 weeks. Two-way repeated measure analysis of variance (ANOVA)
was applied to calculate the significant difference between the total polyp, small polyp and
large polyp count between different groups at different ages. *p<0.01 vs 8 weeks within
the same group. **p<0.02 16 weeks vs 12 weeks within the same treatment group. #p<0.01
ApcMin/+-Control vs ApcMin/+-ABT at 16 weeks of age.
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Figure 4.3. Goblet and epithelial cell production: Figure illustrates (A) Alcian blue
staining for small intestine tissue sections of WT and ApcMin/+ mice with and without
antibiotic treatment. Blue and pink staining indicates goblet and epithelial cells
respectively. (B) and (C): Graphs showing goblet to epithelial cell ratio per view per group
for WT (B) and ApcMin/+ (C) mice. Two-way and two-way ANOVA was used to determine
the significant difference in goblet to epithelial cell ratio between and within groups. *p
value<0.05 vs 8 weeks within treatment group, **p<0.01 ApcMin/+ control mice 16 vs 12
weeks. #p<0.01 control vs ABT group.

Figure 4.4. Intestinal microbiome phylum profiles. Relative percentages of the major
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental
mice at (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage values
represent fractions of depicted bacteria out of the total microbial pool). Two-way analysis
of variance (ANOVA) was used to calculate the significant difference between the
percentage of bacteria in ApcMin/+ control, ApcMin/+ ABT treated, WT ABT treated and WT
control mice at age 8, 12 and 16 weeks. *p<0.05 vs ApcMin/+ 8 weeks, **p<0.05 ApcMin/
+_

(12 weeks vs 16 weeks) and #p<0.01 ApcMin/+ or ApcMin/+ ABT treated or WT ABT

treated vs WT.$p<0.001 WT ABT treated and ApcMin/+ ABT treated vs ApcMin/+ control.
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Figure 4.1. Clinical score with antibiotic treatment. (A–C) Clinical scores for ApcMin/+
mice at different time points (8, 12 and 16 weeks) (n=4 for each group) during the study.
The scores were calculated out of twelve points; four points for each parameter: weight
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA)
was applied to calculate the significant difference between the clinical scores between
different groups. #p<0.03 vs WT-ABT, *p<0.04 vs ApcMin/+-Control group at 6 weeks,
**p<0.03 ApcMin/+-ABT 16 weeks vs 12 and 8 weeks, $p<0.05 vs ApcMin/+ within the same
age group and φp<0.05 ApcMin/+-ABT at 16 weeks vs ApcMin/+-ABT at 14, 12, 10, 8 and 6
weeks of age.
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Figure 4.2. Tumor Quantification: (A) Graph representing the small intestine polyp
count in ApcMin/+-Control and ApcMin/+-ABT at 8 weeks, 12 weeks and 16 weeks after 1, 2
and 3 cycles of antibiotics respectively. (B) Graph showing polyp number (size < 1mm2)
at 8 weeks, 12 weeks and 16 weeks. (C) Graph showing polyp number (size < 1mm2) at 8
weeks, 12 weeks and 16 weeks. Two-way repeated measure analysis of variance (ANOVA)
was applied to calculate the significant difference between the total polyp, small polyp and
large polyp count between different groups at different ages. *p<0.01 vs 8 weeks within
the same group. **p<0.02 16 weeks vs 12 weeks within the same treatment group. #p<0.01
ApcMin/+-Control vs ApcMin/+-ABT at 16 weeks of age.
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Figure 4.3. Goblet and epithelial cell production: Figure illustrates (A) Alcian blue
staining for small intestine tissue sections of WT and ApcMin/+ mice with and without
antibiotic treatment. Blue and pink staining indicates goblet and epithelial cells
respectively. (B) and (C): Graphs showing goblet to epithelial cell ratio per view per group
for WT (B) and ApcMin/+ (C) mice. Two-way and two-way ANOVA was used to determine
the significant difference in goblet to epithelial cell ratio between and within groups. *p
value<0.05 vs 8 weeks within treatment group, **p<0.01 ApcMin/+ control mice 16 vs 12
weeks. #p<0.01 control vs ABT group.
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Figure 4.4. Intestinal microbiome phylum profiles. Relative percentages of the major
phyla obtained from fecal 16S rRNA (V4 region) sequencing analysis from experimental
mice at (A) Proteobacteria, (B) Firmicutes and (C) Bacteroidetes (C). (Percentage values
represent fractions of depicted bacteria out of the total microbial pool). Dotted line
represents WT-C group as a comparative baseline. Two-way analysis of variance
(ANOVA) was used to calculate the significant difference between the percentage of
bacteria in ApcMin/+ control, ApcMin/+ ABT treated, WT ABT treated and WT control mice
at age 8, 12 and 16 weeks. *p<0.05 vs Apc-min 8 weeks, **p<0.05 Apc-min (12 weeks vs
16 weeks) and #p<0.01 Apc-min or ApcMin/+ ABT treated or WT ABT treated vs
WT.$p<0.001 WT ABT treated and ApcMin/+ ABT treated vs ApcMin/+ control.
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CHAPTER 5

ASSOCIATION OF BACTEROIDETES AND FIRMICUTES WITH INFLAMMATION IN
APCMIN/+ MOUSE 3

3

Kamaljeet Kaur, Arpit Saxena, Samantha Truman, Matthew Rorro, Bianca Larsen, Emma
Fletcher, Alexander Chumanevich and Raja Fayad. To be submitted
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5.1 Abstract

The induction of cancer in the gut by chronic inflammation has always indicated
towards the importance of underlying altered inflammatory processes. Apart from
chemopreventive agents that act by modulating and alleviating harmful inflammation, the
intestinal commensal bacteria also plays a role in the development of gut
microenvironmental immune system and maintains a protective steady state immune
function throughout life. The systemic release of microbial products as a result of insults
to gut epithelium has been associated with inflammation-related colon cancer and the
present study aimed at characterizing this association. 4 weeks old ApcMin/+ and C57BL/6
(WT) mice were housed at the Animal Resource Facility, University of South Carolina
with access to food and water ad libidum. The ApcMin/+ and C56BL/6 mice were assigned
to the following groups: WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8
weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16
weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks,
ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. An
antibiotic mixture containing Vancomycin, Neomycin and Ampicillin (each 1 mg/mL) was
administered to experimental mice through drinking water starting at the 5th, 10th and 14th
weeks of age for 10 days followed by normal drinking water. Small intestinal paraffinembedded sections were used for performing hematoxylin and eosin staining to determine
the histopathology of small intestine and colon epithelial layer and for calculating crypt
depth to villus ratio (CVR). Spleen weight was also measured to quantify general
inflammation. The antibiotic treatment caused a physical insult to the intestinal mucosa
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and caused a reduction in spleen weight. The CVR increased significantly with antibiotic
treatment in the WT mice as compared to controls at all three time points, while its increase
was significant only at 12 weeks in case of ApcMin/+ mice. The overall of percentage of
Firmicutes increased with antibiotic treatment. It could be concluded that the effects of an
altered microbiome may have both physical and physiological effects during initiation and
progression of tumorigenesis. These effects may manifest as an insult to the intestinal
mucosa, reduced spleen size and increased CVR, and may also be enhanced by an increased
percentage of the Firmicutes phylum.

Keywords: Firmicutes, inflammation, polyp, gut microbiome, crypts

5.2 Introduction
A need to address and characterize host-microbe relations has been emphasized in
recent years in order to elucidate the processes and factors involved in the relationship
between the gut microbiome and inflammation and related tumorigenesis. Alterations in
the gut microbiota have been linked to a dysregulation of the regulatory T cell paradigm
and their associated cytokines (Shen, et al., 2014), where the regulation of this
immunological pathway depends on the relationship between the gut microbiota and the
immune system. There have been no studies that study the gut microbiome with respect to
gut inflammation and tumorigenesis in an age/time- dependent manner. It has been seen
that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor load and anemia with a
higher infiltration of inflammatory cells specifically at advanced stages as compared to
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germ-free animals, indicating that a mere modulation of gut microbiome profiles can
abrogate the disease condition in the gut (Y. Li, et al., 2012).
The significance of inflammation as a process underlying and crucial to cancer is
demonstrated by the fact that till date, one of the most effective class of chemopreventive
agents is the non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in
the gut by chronic inflammation has always indicated towards the importance of underlying
altered inflammatory processes (Zhang, et al., 2015). Different agents that have been
documented to be effective against tumors and cancers are the agents that function by
downregulating important inflammatory pathways and pro-inflammatory cytokines. It has
also been shown that the intestinal commensal bacteria play a role in the development of
the immune system of the gut microenvironment comprising both the humoral and cellular
components and maintains the protective steady state immune function throughout life
(Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any alteration
in the composition of the gut microbiome leads to a dysfunctional immune system. Certain
bacterial species such as B. thetaiotaomicron bacterium have been associated with the
attenuation of pro-inflammatory responses by reducing the levels of the pro-inflammatory
cytokine IL-8 (Zhao, et al., 2001). Comparative numbers of certain bacteria often lead to
upregulation or downregulation of certain inflammatory pathways. The systemic release of
microbial products as a result of the manipulation of the gut epithelium invokes an IL-23
response and a further IL-17 response in order to neutralize further invasion by the
microbes, and the process is brought about by the bacteria Clostridia sp. (Shih, et al., 2014).
Other bacterial species may also be involved with anti-inflammatory effects such as the
bacteria Bacteroides fragilis from the Bacteroidetes phylum leads to an increase in the
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production of IL-10 cytokine (Omenetti & Pizarro, 2015). It has been suggested that the
interplay of inflammation and tumorigenesis is modulates strongly by the gut microbiota
but the mechanisms leading to the process have not elucidated. Recently, some light has
been shed on the phenomena by a study which could demonstrate the process of
tumorigenesis to occur in germ-free mice when transplanted with isolated gut microbiota
from intestinal tumor-bearing mice (Zackular, et al., 2013).
The establishment and diversification of the gut microbiome is a gradual process
that is required for proper development and overall health. Once the gut microbiome
manifests itself completely, its stays constant during the life of a healthy individual (Franks,
et al., 1998) which explains the fact that an alteration in one or more of the resident
microbial populations lead to pathological conditions.
The Bacteroidetes phylum is comprised of Gram-negative anaerobic and aerobic
bacterial species. Some studies link the absence or reduction of, or delayed colonization of
the gut by the phylum Bacteroidetes to be associated with a weakened immune system in
humans. For example, a delayed postnatal colonization of Bacteroidetes population has
been associated with development of allergies in children born by Caesarian section (S.
Watanabe, et al., 2003).
The Firmicutes represent the phylum mostly containing Gram-positive bacterial species.
The phylum contains both aerobic and anaerobic bacterial species.
Many Firmicutes are capable of producing endospores which help them survive desiccation
and extreme conditions. Their capability to survive extreme conditions may be one reason
that these bacteria are found in high numbers in the gut under pathological and
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inflammatory conditions. Comparisons of gut microbiota of lean and obese mice and lean
and obese human individuals revealed that the Bacteroidetes significantly decrease while
the Firmicutes significantly increase with obesity (Guo, et al., 2008).
An altered ratio between the two main gut bacterial phyla Bacteroidetes and
Firmicutes may help elucidate at least way through which the gut changes during initiation
of progression of tumorigenesis.

5.3 Material and Methods

Experimental animals and groups
4 weeks old ApcMin/+ and C57BL/6 (WT) mice were obtained from Jackson Laboratories
and bred in-house at the Animal Resource Facility, University of South Carolina. Food
(Purina chow) and drinking water was available to the mice ad libidum under a 12:12 hour
light-dark cycle and a low-stress environment (22oC, 50% humidity and low noise). The
ApcMin/+ and C56BL/6 mice were assigned to the following twelve groups with four mice
in each group (n=4): WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8 weeks,
WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16 weeks,
ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks, ApcMin/+ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. Experimental
animals from aim 1 were used for aim 2 as control animals. All animal care followed
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institutional guidelines under a protocol approved by the Institutional Animal Care and Use
Committee at the University of South Carolina.
Histopathology
Small intestinal paraffin-embedded sections from aim 2 were used for performing
hematoxylin and eosin staining in order to determine the morphology of small intestine and
colon epithelial layer. Histopathology were quantified visually in a double-blind condition
using light microscopy by a pathologist. Localized inflammatory status were indicated by
inflammatory cells present in the mucosal layers of intestine and colon. Aberrant villi and
crypts were also used as indicators of intestinal and colonic insults due to inflammatory
response.
Hematoxylin and eosin staining was used to observe the morphology of the intestinal
mucosa and the disease severity was quantified on the basis of inflammation, immune cell
infiltration into the mucosa and degree of tumor. Histopathology was quantified based on the
scoring system indicating the severity of disease and constituting inflammation and immune cell
infiltration. This was on the scale of 8 where highest score of 4 was given for each parameter, where
0 = no infiltration or no inflammation; 2 = moderate infltration or inflammation; and 4 = severe
inflammation with distorted crypts or infiltration and formation of lymphatic follicles (Saxena et
al., 2009).. All the images were taken in 20X magnification with Nikon e600 microscope. Two
investigators in blinded fashion measured the scores independently and the average was plotted in
a graph.”
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Crypt depth to villus height ratio
Paraffin-embedded 10 µm small intestinal sections were deparaffinized and stained with
hematoxylin and eosin. Digitized images of the tissues were obtained using a digital camera
connected to a light microscope. The images were analyzed in a double blinded manner
using the digital image software ImageJ, and crypt depth and villus height were measured
(mm/mm) to calculate the crypt depth to villus height ratio.
Spleen weight
Spleens were excised from the animals at the time of sacrifice and their weights were
recorded to estimate levels of systemic inflammation. The spleen samples were then rinsed
with PBS and snap frozen.

Enzyme-linked Immunosorbent Assay
Enzyme-linked Immunosorbent Assay (ELISA) was performed to calculate the levels of
pro-inflammatory cytokines TNF-α, IL-1β and IL-17 using kits (BD Pharmingen). The
ELISA were performed on serum to know the levels of systemic cytokines. At the time of
sacrifice, 1 cm sections of ileum and distal colon were excised from the experimental mice
and incubated in 1 mL of RPMI medium at 37oC for 24 hours. The medium incubated with
the excised tissues was then collected into separate centrifuge tubes and centrifuged at 4000
rpm at 25oC for 15 minutes. The supernatant collected from the centrifuged contents served
as the sample containing small intestine or colon tissue-secreted cytokines.
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Statistical analysis
Two-way analysis of variance (ANOVA), Two-way repeated measure ANOVA and Oneway ANOVA were used to analyze the data with Tukey post hoc-analyses to estimate the
significance of differences obtained between different experimental treatment conditions
and between the experimental mouse strains used in the study. A p<0.05 were considered
statistically significant. All the statistical analyses were done using SigmaStat 3.5 (SPSS,
Chicago, IL).

5.4. Results

Histopathology
Histopathology of the small intestine was revealed by hematoxylin and eosin staining.
Signs of inflammation were observed during all stages of tumorigenesis in the intestinal
tissue of ApcMin/+ mice. Hyperplasia was observed in all ApcMin/+ mice at 8 weeks with and
without antibiotic treatment. Mucosal dysplasia, blunted villi and increased monocytic
inflammation was observed at 12 weeks. High grade chronic-type inflammation as shown
by the presence of plasma cells and macrophages but no neutrophils was observed at 16
weeks in the ApcMin/+ mice without antibiotic treatment. High grade dysplasia and
dysplastic lesions were observed with antibiotic treatment in the ApcMin/+ mice at 16 weeks
as compared to low-grade dysplasia that was observed at 16 weeks without antibiotic
treatment (figure 5.1 A).
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Histopathology scoring was used to determine quantitative difference in the histopathology
of the colon of the mice belonging to different groups and with age. Degree of inflammation
and immune cell infiltration was found to be significantly higher in ApcMin/+ ABT group
when compared to ApcMin/+ control and WT ABT group. All the groups showed
significantly higher clinical score than WT control group. Colon of the mice belonging to
the ApcMin/+ control, ApcMin/+ ABT and WT ABT group showed a significantly higher
inflammation and immune cell infiltration when compared to mice within the same group
at 8 weeks. No significant difference was found between other groups and within group
with age (figure 5.1 B).

Spleen Weight
Spleen weight was assessed as a measure of systemic inflammation along with serum
cytokines. Spleen weight of ApcMin/+ ABT group at 16 weeks and ApcMin/+ control group at
12 and 16 weeks was found to be significantly higher than the mice within the same groups
at 8 weeks of age. Spleen weight of ApcMin/+ ABT and ApcMin/+ control group mice at 16
weeks of age was found to be significantly higher than both WT control mice and within
the same group at 12 weeks of age. ApcMin/+ control group mice was found to have a
significantly higher spleen weight as compared to the WT control mice (figure 5.2A).
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Crypt depth to villus height ratio (CVR)
The crypt depth to villus ratio (CVR) was calculated as a measure of intestinal
inflammation for all animals. The CVR ratio in both ApcMin/+ and WT group with ABT at
12 and 16 weeks was found to be significantly higher than the mice within the same group
at 8 weeks of age. The CVR ratio of WT and ApcMin/+ with ABT treatment was 12 weeks
of age was found to be significantly higher than the control mice with the same genotype.
Spleen weight of the WT mice with ABT treatment was significantly higher at 16 weeks
of age when compared to WT control at the same age. ApcMin/+ control mice at 16 weeks
of age was found to have significantly higher CVR ratio when compared to the control
mice at 12 weeks of age with the same genotype. NO significance was found between other
treatment groups and with age in the same treatment group with same or different genotype
(figure 5.3 A and B).

Cytokines
The pro-inflammatory cytokines TNF-α, IL-1β and IL-17 did not show any significant
difference between the experimental groups when measured for their levels in the serum
(systemic) (figure 5.2 B,C and D) and as secreted by the small intestine and colon (tissuelevel) (figure 5.3 C, D, E and F)suggesting that an alteration in gut microbiome may not
significantly affect the systemic and tissue-level inflammation.
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5.5. Discussion

The present study aimed at defining the inflammatory effects of an altered gut
microbiome with relation to stages of tumorigenesis. We have found previously that the
manipulation of the gut microbiome through usage of antibiotics significantly decreases
the goblet to epithelial cell ratio in the small intestine of ApcMin/+ and WT experimental
mice. A reduction in the number of goblet cells reduces the production of the protective
intestinal mucus, which thins over time until eventually lost thus exposing the underlying
mucosa to possible physical erosion by the presence of antibiotics in the intestinal lumen.
In the present study, the physical harmful effects of gut microbiome manipulation were
observed to lead to the recruitment of certain inflammatory cells to the eroded mucosal
sights. While damaged crypts result in the WT mice, the ApcMin/+ mice exhibit effects
ranging from low-grade dysplasia to high-grade dysplasia, neutrophil and monocyte
infiltration and villus edema, corroborating our previous findings that the use of antibiotics
has an additive effect on gut health along with factors such as inflammation, polyp numbers
and mucus production. The spleen weighs were significantly reduced with antibiotic
treatment only in the ApcMin/+ mice, which indicates that the antibiotic treatment does not
have any effect under normal conditions (Prior, Gander, Irache, & Gamazo, 2005; Reikvam
et al., 2011). The significant difference in the spleen size between antibiotic treatment and
control within the ApcMin/+ mice may reflect an effect of reduced immune system function
as a result of inflammation caused due to tumorigenesis. Interestingly, the spleen weights
were significantly higher in the ApcMin/+ as compared to those of the WT mice at 16 weeks,
which may support the idea that a longer period of microbiome manipulation may lead an
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even lower spleen weight in the WT but is not able to decrease it to the same level under
tumorigenic conditions. However, out results from cytokine analyses failed to reiterate our
spleen results as the serum cytokine levels were not significantly altered following
antibiotic administration in both WT and ApcMin/+ mice. A higher samples size may help
better standardize the effects of the antibiotics and microbiome manipulation on spleen size
during tumorigenesis.
The CVR was also not significantly different between antibiotic-treated and control
groups at 8 weeks, indicating a relatively balanced inflammatory status of the experimental
animals at the initiation of tumorigenesis. The CVR increases significantly in the treatment
group as compared to the control groups of animals at 12 weeks indicating an
inflammatory-inducing effect of antibiotics on both the strains of mice. An absence of any
difference between the antibiotic-treatment and control in the ApcMin/+ mice at 16 weeks is
probably due to similarities between the measurements for antibiotic treatment and control.
This observation, when compared to the WT mice indicates a healthier intestinal CVR
during the absence of antibiotics which is abrogated once the WT intestine is exposed to
the antibiotics. However, an absence of secretion of pro-inflammatory cytokines by the
small intestine and colon indicates towards a more physical effect of the antibiotic
treatment than that on the physiology of the intestinal and colon tissues. A larger sample
size may help to elucidate the physiological effects more coherently.
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5.6. Conclusion
In conclusion, the effects of gut microbiome manipulation through antibiotic
treatment could not be established on the ApcMin/+ mouse clinical scores, spleen weights
and CVR, and only some of the physical effects of erosion and insult to the intestinal
mucosa could be established. A larger samples size will be required to support or negate
the findings of the present study.
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5.7. Figure Legends

Figure 5.1. Histopathology: (A) Hemeatoxylin and eosin stained small intestinal tissues
belonging to the WT and ApcMin/+ mice with and without antibiotic treatment at different
ages of mice. (B) Histopathology scoring determining the degree of inflammation and
immune cell infiltration was plotted for different treatment group at different age. Twoway analysis of variance (ANOVA) was used to calculate the significant difference
between different treatment groups at different ages. *p<0.05- Apc-min-ABT vs Apc-min-
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C, *p<0.05- Apc-min-C vs WT-ABT, #p<0.01- Apc-min-ABT vs WT-ABT, ***p<0.05
16 weeks vs 8 weeks.

Figure 5.2. Systemic inflammation: Figure illustrating systemic inflammation in the form
of (A) spleen weights (grams) for all four experimental groups and serum proinflammatory cytokine (B) IL-17, (C) IL-1β and (D) TNF-α levels for the experimental
groups. Two-way analysis of variance (ANOVA) was used to calculate the significant
difference between different treatment groups at different ages. *p value<0.05 vs 8 weeks
within the same treatment group. #p<0.05 vs WT control and **p<0.05 16 weeks vs 12
weeks.

Figure 5.3. Tissue-level inflammation: Figure illustrating tissue-level inflammation in
the form of small intestinal crypt depth to villus height ratio (CVR) between different
experimental groups for (A) WT and (B) ApcMin/+ mice; and small intestine-secreted levels
of pro-inflammatory cytokines (C) IL-17, (D) Il-1β and (E) TNF-α; and colon-secreted
levels of pro-inflammatory cytokines (F) IL-17, (G) IL-1β and (H) TNF-α. Two-way
analysis of variance (ANOVA) was used to calculate the significant difference between
different treatment groups at different ages. *p value<0.04 vs 8 weeks, #p<0.01 ABT vs
control group and **p<0.05 16 vs 12 weeks within the same group.
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Figure 5.1. Histopathology: (A) Hemeatoxylin and eosin stained small intestinal tissues
belonging to the WT and ApcMin/+ mice with and without antibiotic treatment at different
ages of mice. (B) Histopathology scoring determining the degree of inflammation and
immune cell infiltration was plotted for different treatment group at different age. Twoway analysis of variance (ANOVA) was used to calculate the significant difference
between different treatment groups at different ages. *p<0.05- Apc-min-ABT vs Apc-minC, **p<0.05- Apc-min-C vs WT-ABT, #p<0.01- Apc-min-ABT vs WT-ABT, ***p<0.05
16 weeks vs 8 weeks.
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Figure 5.2. Systemic inflammation: Figure illustrating systemic inflammation in the form
of (A) spleen weights (grams) for all four experimental groups and serum proinflammatory cytokine (B) IL-17, (C) IL-1β and (D) TNF-α levels for the experimental
groups. Two-way analysis of variance (ANOVA) was used to calculate the significant
difference between different treatment groups at different ages. *p value<0.05 vs 8 weeks
within the same treatment group, #p<0.05 vs WT control and between ApcMin/+-C vs
ApcMin/+- ABT, and **p<0.05 16 weeks vs 12 weeks.
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Figure 5.3. Tissue-level inflammation: Figure illustrating tissue-level inflammation in
the form of small intestinal crypt depth to villus height ratio (CVR) between different
experimental groups for (A) WT and (B) ApcMin/+ mice; and small intestine-secreted levels
of pro-inflammatory cytokines (C) IL-17, (D) Il-1β and (E) TNF-α; and colon-secreted
levels of pro-inflammatory cytokines (F) IL-17, (G) IL-1β and (H) TNF-α. Two-way
analysis of variance (ANOVA) was used to calculate the significant difference between
different treatment groups at different ages. *p value<0.04 vs 8 weeks, #p<0.01 ABT vs
control group and **p<0.05 16 vs 12 weeks within the same group.
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CHAPTER 6
OVERALL DISCUSSION
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Our first experiment was aimed at studying alterations in the gut microbiome at the stages
of tumor initiation and progression in an age-dependent manner using a spontaneouslydeveloping tumor mouse model. We hypothesized that an increase in the levels of
Firmicutes and a reduction in the Bacteroidetes levels would be associated with
tumorigenesis. We also hypothesized that the process of tumorigenesis will result in lower
diversity values of gut microbiome. We found that the Firmicutes were significantly higher
than the Bacteroidetes during tumorigenesis at all three ages – 8, 12 and 16 weeks,
indicating that the Firmicutes may be precursors to tumorigenesis. While this was true, the
diversity values (supplemental data) were not significantly different between tumorbearing and control mice, indicating that the overall diversity may not be indicative of
tumorigenesis as can be the altered levels of certain phyla. The Firmicutes phylum was the
only factor that was seen to be increased in the tumor-bearing mice as compared to the WT
mice. The fact that the WT mice did not show any clinical score makes Firmicutes the
likely bacterial phylum that can set the stage for tumorigenesis. The observation that the
clinical scores for tumor-bearing mice continued to increase until 16 weeks may indicate
that levels of Firmicutes may not correlate with disease prognosis once the process of
tumorigenesis begins.
The relationship between altered percentages of the Firmicutes and Bacteroidetes
phyla populations, and tumor number, tumor size and mucus-producing goblet cell
numbers has not been previously examined. The regulation of the mucin gene expression
as well as mucus production have been shown to be two levels at which the gut microbial
community may modulate mucins (Comelli, et al., 2008). Our second study was aimed at
following the processes of tumorigenesis, resulting disease prognosis, and intestinal mucus
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secretion phenotype after microbial manipulation at three different time points – 8, 12 and
16 weeks. We hypothesized that the manipulation of the gut microbiota would lead to a
loss in gut health and an increase in tumor number and size in the ApcMin/+ mouse.
Furthermore, manipulation of the gut microbiota would decrease goblet cell number in the
intestine and colon. While our first study showed a progressive decrease in the percentage
of Firmicutes population in tumor-bearing mice under normal conditions, the phylum
showed a similar trend in the control groups while continuing to remain high even at 12
(tumor development) and 16 weeks (later stages of tumorigenesis) of age with antibiotic
treatment. Our data may support other studies that demonstrated that even when the
antibiotic treatment is stopped, and some resilient bacteria repopulate the gut, the final state
is never a complete replacement of the initial state (Francino, 2015). Our clinical score
continued to remain high at 12 and 16 weeks for the ApcMin/+ with and without antibiotic
treatment and for WT mice with antibiotic treatment and correlated to the time points of
antibiotic administration to the mice. The external manipulation of the gut microbiome
induced effects on the physiology of the intestine as well, as can be seen from the data on
the polyp numbers of the ApcMin/+ mice. The manipulation of gut microbiome significantly
increased the polyp numbers at 16 weeks as compared to those at 12 weeks with antibiotic
treatment. This implicates a role for the antibiotic treatment in the later stages of
tumorigenesis, which is not seen under tumorigenic conditions without antibiotic treatment
where the polyps increase in their size and not numbers from 12 weeks to later stages of
tumorigenesis (McClellan, Davis, Steiner, Enos, et al., 2012). The effects of antibiotic
treatment or gut microbiome manipulation followed a similar trend in case of polyps that
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measured more than 1 mm in diameter, while had no significant effect on polyps less than
1 mm diameter.
Our study also demonstrated a significant reduction in the ratio of intestinal goblet
to epithelial cells at all three time points, indicating the potential for the gut microbiome to
influence mucus-producing phenotype of the cells comprising the intestinal mucosa.
Histopathological observations of intestinal mucosa in the third part of the present study
revealed a significant increment in the levels of inflammation and cellular infiltration in
antibiotic-treated ApcMin/+ mice as compared to the control ApcMin/+ and antibiotic-treated
WT mice at 8, 12 and 16 weeks indicating an inflammatory effect of antibiotic treatment,
which is more pronounced during tumorigenic conditions. The levels of inflammation and
cellular infiltration were significantly higher at 16 weeks as compared to those at 8 weeks
for ApcMin/+-ABT, ApcMin/+-C and WT-ABT mice, but not at 12 weeks, indicating that not
only the inflammatory responses following antibiotic treatment may exacerbate during
tumor-bearing conditions and but antibiotic treatment may bring about significant
inflammatory responses even in control conditions. A loss in the protective mucus in the
gut lumen may be a reason for such an effect, however, we did not investigate such an
interrelationship directly. We hypothesized for aim 3, an increase in systemic and tissuelevel inflammation with gut microbial manipulation with antibiotic administration. We
found that spleen weight which is an indicator of systemic inflammation, increased
significantly at 12 and 16 weeks as compared to 8 weeks in the ApcMin/+ mice under control
conditions and antibiotic-treatment conditions which indicates an increased inflammatory
response of tumorigenesis and microbiome manipulation. However, within 12 and 16
weeks, the spleen weights were significantly reduced with antibiotic administration, an
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effect that negated our hypothesis of an increased systemic inflammation with antibiotic
administration. Our data on serum cytokines was not conclusive on systemic inflammation.
We also hypothesized an increase in tissue-level inflammation with antibiotic-mediated gut
microbial manipulation. We measured CVR for an estimate of the same. The gut microbial
manipulation significantly increased the CVR for both ApcMin/+ and WT mice at 12 and 16
weeks as compared to 8 weeks indicating a shift towards a more pronounced tissueinflammatory response at 12 and 16 weeks. The antibiotic treatment increased the CVR
significantly at 12 and 16 weeks for the WT mice but only at 12 weeks for the tumorbearing ApcMin/+ mice, suggesting that gut microbial manipulation may be important for
tissue level inflammation during progression of tumorigenesis. However, our data on
tissue-secreted cytokines could not corroborate our findings on CVR indicating towards an
effects of antibiotics exposure on intestinal mucosal morphology rather than on its secreted
cytokines.
Summary
By means of this dissertation, we demonstrated that while certain members of the gut
microbiome and any alterations thereof may seem to affect the process of tumorigenesis,
there numbers and relative numbers may not affect the disease prognosis. The way by
which the gut microbiome is altered may also play an important role in the way we see
processes that are linked to tumorigenesis in the gut most importantly the physical aspects
of the gut lumen. An externally manipulated gut microbiome specifically through
antibiotics can disrupt the mucosal lining producing, under normal conditions, symptoms
same as those manifested under tumor-bearing conditions. The effects of the method of gut
microbiome manipulation through antibiotics seems to be more due to the physical effects
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of the antibiotic rather than an altered gut microbiome. The polyp number increased with
antibiotic administration as compared to untreated tumor-bearing conditions. Other
physiological alterations and possible routes through which intestinal insult can result is
the reduction in the size of the villi lining the absorptive surface of the intestinal lumen and
hampering the development of goblet cells that produce protective mucus on the luminal
surface. While antibiotics used to manipulate the gut microbiome may be broad-ranged and
less specific, certain phyla of bacteria may be more susceptible to the same combination of
the antibiotics as compared to others. In our study, while the Bacteroidetes phylum of
bacteria is severely susceptible to the antibiotic treatment leading to negligible levels in the
experimental groups with microbiome manipulation, Firmicutes phylum seem to thrive
more than in normal conditions with the use of antibiotics. However, larger samples sizes
with specific pathogen-free experimental conditions could be helpful for better
understanding the role of certain classes of gut microbial community in processes such as
tumorigenesis and inflammation.

Future directions
Studies on topics of the present dissertation need to be highly controlled and specific. The
usage of specific pathogen-free animals or antibiotics against specific microbial
community/communities will be necessary to better understand the role of specific classes
of gut microbiome in disease processes such and inflammation and tumorigenesis. Another
highly controlled and specific method to elucidate the role(s) of gut microbiota on
inflammation and tumorigenesis and other disease conditions is the use of germ-free
animals.
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S1

Figure S1: Alpha diversity values ApcMin/+-C and WT-C: Figure illustrating box plots
of alpha diversity values obtained between ApcMin/+ and WT mice under control conditions
and significance values obtained by Kruskal-Wallis statistical analysis where p value>0.05
was considered significant. (OTUs: Observed Taxonomic Units between the two groups;
Chao1 index: Estimator of richness between the two groups; and Shannon index: Estimator
of richness and evenness between the two groups). The three horizontal lines contained
within each box plot represent the third quartile, median and first quartile (from top to
bottom). The vertical lines on top and bottom of the box plot represent the maximum and
minimum values plotted respectively.

S2(A)
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S2(B)

S2(C)

Figure S2: Alpha diversity values. Figure illustrating box plots of alpha diversity values
obtained between (A) ApcMin/+-ABT and ApcMin/+-C; (B) WT-ABT and WT-C; and (C)
WT-C/ABT and ApcMin/+-C/ABT. Significance values were obtained by Kruskal-Wallis
statistical analysis where p value>0.05 was considered significant. (OTUs: Observed
Taxonomic Units between the two groups; Chao1 index: Estimator of richness between the
two groups; and Shannon index: Estimator of richness and evenness between the two
groups). The three horizontal lines contained within each box plot represent the third
quartile, median and first quartile (from top to bottom) respectively. The vertical lines on
top and bottom of the box plot represent the maximum and minimum values plotted
respectively.
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Alcian Blue Staining Protocol
Solutions and Reagents:
3% Acetic Acid Solution:
Glacial acetic acid ----------------- 3 mL
Distilled water --------------------- 97 mL
Alcian Blue Solution (pH 2.5):
Alcian blue, 8GX -------------------- 1 g
Acetic acid, 3% solution ----------- 100 mL
Mix well and adjust pH to 2.5 using acetic acid.
0.1% Nuclear Fast Red Solution:
Nuclear fast red ------------------- 0.1 g
Aluminum sulfate------------------ 5 g
Distilled water ---------------------100 mL
Dissolve aluminum sulfate in water. Add nuclear fast red and slowly heat
to boil and cool. Filter and add a grain of thymol as a preservative.
Procedure:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Deparaffinize slides and hydrate to distilled water.
Stain in Alcian Blue solution for 30 minutes.
Wash in running tap water for 2 minutes.
Rinse in distilled water.
Counterstain in nuclear fast red solution for 5 minutes.
Wash in running tap water for 1 minute.
Dehydrate and through 95% alcohol, 2 changes of absolute alcohol,
3 minutes each.
Clear in xylene or xylene substitute.
Mount with resinous mounting medium.

121

Hematoxylin and Eosin Staining Protocol
1. Deparaffinize in Xylene I and II and III (3 minutes)
2. Rehydrate
a. EtOH 100% (3 minutes)
b. EtOH 100% (3 minutes)
c. EtOH 95% (3 minutes)
d. EtOH 95% (3 minutes)
e. EtOH 70% (3 minutes)
3. Rinse in distilled water (5 minutes)
4. Stain in hematoxylin (6 minutes) Filter before each use to remove
oxidized particles
5. Rinse in running tap water (15 minutes)
6. Decolorize in acid alcohol (1 second)
7. Rinse well in tap water (5 minutes)
8. Immerse in ammonia water (3 Seconds)
9. Rinse in tap water (5 minutes)
10. Counterstain in Eosin (15 seconds)
11. Dehydrate
a. EtOH 95 % (3 minutes) Discard after each use
b. EtOH 95% (3 minutes)
c. EtOH 100 % (3 minutes)
d. EtOH 100 % (3 minutes)
12. Clear in Xylene I and II (5 minutes)
13. Mount with Cytoseal in fume hood.
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Summary
Background and significance: The microbiome forms an integral part of the gut
microenvironment. Once ignored, the topic has gained momentum in research during the
past decade, where studies have strongly suggested the association of microbiota with
health and a misbalance thereof, to many disease conditions ranging from inflammation
and colitis to diabetes, obesity and colon cancer. The Human Microbiome Project (HMP,
NIH common fund - 2008) has used a variety of high throughput analyses in order to study
gut microbiota in health. The consortium has so far been able to isolate and characterize
more than 1,300 reference bacterial strains from the human body. The large amount of data
generated has led to a baseline need to address the implications of different microbial
members, or groups thereof, in health and disease. The microorganisms residing in the gut
comprise of bacteria, archaea, fungi and viruses that are distributed throughout the length
of the gastrointestinal tract. While there will be limitations to studying all types of
microorganisms owing to their overwhelming numbers and types, our study is focused only
on bacterial populations of the gut, and for the purpose of convenience, terms of gut
microbiota/microbiome will be used for describing gut bacteria pertaining to the mice used
in our study. The overall purpose of this study is to determine the effects of alterations in
the gut microbiome on tumor development and inflammation, and if it leads to
recolonization of the gut by altered bacterial communities. The working hypothesis is that
an alteration of bacterial microbiome will occur during tumorigenesis and manipulation of
the gut microbiome externally will exacerbate the clinical symptoms associated with
intestinal cancer, leading to higher gut and systemic inflammation.
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To test this hypothesis, the following specific aims will be used:
Specific Aim 1: To examine the composition of gut microbiome during tumor
initiation and development in the ApcMin/+ mouse.
Specific Aim 2: To determine if gut microbiome manipulation can regulate the
ApcMin/+ mouse gut health and tumorigenesis.
Specific Aim 3: To determine if the relative abundance of Bacteroidetes and Fimicutes
bacterial populations is associated with intestinal and systemic inflammation in the
ApcMin/+ mouse.

The primary objectives of this study are to: 1) determine whether the gut microbiome
profiles change during early and later stages of tumorigenesis, 2) determine the effect of
external manipulation of gut microbiome on tumor load and size, and on mucus-producing
goblet cell population in the gut, 3) study any alterations in the bacterial populations
pertaining to the Bacteroidetes and Firmicutes phyla that recolonize after external
manipulations of the gut microbiome, 4) determine if altered Bacteroidetes and Firmicutes
populations increases tissue inflammation in the intestine, 5) determine if altered
Bacteroidetes and Firmicutes populations lead to an increase in circulatory cytokines. The
rationale behind our study are the research studies that have been published and our
preliminary data. It has been shown that the gut microbiota accelerates tumor growth in the
ApcMin/+ mice through the c-jun/JNK and STAT3 phosphorylation pathways and causes a
vicious cycle of inflammation in the intestine (Y. Li, et al., 2012). Recently, it has also
been demonstrated that alterations in the gut microbiota precede tumor development in the
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ApcMin/+ mice (Son, et al., 2015) which is due to the resulting alterations in interactions of
gut microbiota and gut mucosa. The novelty of the present study is in answering the
question as to how the gut microbiome shifts from early to later stages of tumorigenesis.
Studies do indicate that the gut microbiota can be a potential target in the amelioration of
cancer progression but it is not known how the microbiome paradigm of the gut shifts with
respect to progression in tumorigenesis. This study will also be directed towards
understanding inflammatory changes and changes in mucus producing function of the gut
and their relation to a change in quantifiable disease severity and microbiota alterations.
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CHAPTER 1
Introduction and Aims
The topic of gut microbiome has recently gained attention due to research suggesting its
significant role in not only maintenance of gut health but also in disease conditions such as
obesity, diabetes, arthritis, colitis and cancers of the digestive system (Cho, et al., 2014;
Dziarski, et al., 2016; Kabeerdoss, et al., 2015; Knip & Siljander, 2016). The gut
microbiome comprises of around 500-1000 species and a genetic diversity which has 100fold more genes than humans (Dugas, et al., 2016).
Another field that aims at answering the questions on gut microbiome and its links
to health and disease is the usage of probiotics including one or more important bacteria.
The bacteria Lactobacillus acidophilus has been implicated in a significant suppression of
colon tumor incidence and size and a reduction in pro-inflammatory cytokines such as
TNF-α and IFN-γ (Perdigon, et al., 1998; Urbanska, et al., 2009). Some studies also state
that the link between the microbiome and the actual development of polyps in the gut is
solely linked through the erosion of the gut lumen microenvironment and the resulting
inflammation (Dianda, et al., 1997).
An altered microbiome has been previously linked to inflammatory bowel disease
and colorectal cancer. However, we still lack the knowledge of a characterizing the gut
microbiome that relates to health or disease condition. An early event of inflammatory
insult to the gut can very well result in tumorigenesis when combined with processes of
bacterial DNA damage and chromatin alterations (Zhu, et al., 2011). Studies on mouse
models such as the IL-10-/- have demonstrated a protective role of the presence of gut
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microbiome on inflammation, where the WT mice were rendered protected against
inflammation in the gut while the germ-free (no microbiome) animals developed colitis (S.
Wu, et al., 2009). It should be noted here that a germ-free animals may not represent the
human gut as an individual can never be completely without microbiome in the gut. From
the perspective of any given disease state that can be linked to microbiome, the basis of its
linkage can only be an altered microbiome. It should also be noted that the process of
inflammation is the one that alters the microbiome (Uronis & Jobin, 2009), although
inflammation alone is not sufficient to promote colorectal cancer and altered microbiota
works hand in hand with inflammatory insults that will eventually lead to cancer (Arthur
& Jobin, 2013). The gut microbiome has been shown to complement AOM and DSS mouse
models in causing tumorigenesis, but is yet to be elucidated if it is the increase or loss of
certain bacterial populations that lead to development of polyps (Zackular, et al., 2013). It
is, however, not known what effect the microbial dysbiosis has at different stages of
progression of tumorigenesis in the mouse, or if it leads to different consequences in normal
versus tumorigenic conditions.

What is unknown?
Studies are needed to characterize the interplay between the gut microbiome, inflammation
and cancer. Another aspect which will be helpful in correctly defining the microbiome and
inflammation-to-cancer axis will be the progression of alterations in the microbiome with
worsening disease pathology. Of all the diseases that are affected by a change or loss of
gut microbiome, cancer of the small and large intestine is clearly the one which can be
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physically and physiologically related to the presence of alterations in gut microbiome
community.

AIM 1: To examine the composition of gut microbiome during tumor initiation and
development in the ApcMin/+ mouse.
Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial
lining that, in turn, leads to more and more inflammatory processes taking place inside the
gut microenvironment (Saxena, et al., 2012; Wang & Zhang, 2015). Our previous study on
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice
demonstrated microbiota profiles that were clearly altered during tumorigenesis (data not
published). The alterations mainly pertained to the altered percentages of the Firmicutes
and Bacteroidetes bacterial phyla during inflammation-induced tumorigenesis in the mice
(Figure 1). As opposed to externally administered chemically-induced tumorigenesis in
mice, the microbiota has not been studied with respect to a spontaneously induced
tumorigenesis such as that in the ApcMin/+ mouse. It was recently concluded that an
alteration of gut microbiome precedes polyposis in the ApcMin/+ mouse (Son, et al., 2015).
Also, it has been seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor
load and anemia with a higher infiltration of inflammatory cells specifically at advanced
stages as compared to germ-free animals, indicating that a mere modulation of gut
microbiome profiles can abrogate the disease condition in the gut (Y. Li, et al., 2012).
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However, there are no studies that study the gut microbiome with respect to gut
inflammation and tumorigenesis in an age/time- dependent manner. Therefore, the first aim
of the present study will be directed towards characterization of alterations of microbiome
profiles from early to later stages of tumorigenesis in an ApcMin/+ mouse model.
Hypothesis: The gut microbiota in ApcMin/+ mice will exhibit a higher percentage of
Firmicutes bacterial phyla and a reduction in the percentage of Bacteroidetes, along with
reduction in overall bacterial diversity during onset of tumorigenesis when compared to
the WT mice. Furthermore, the percentage of Firmicutes will increase, while overall
diversity will decrease during the progression of tumorigenesis.
AIM 1.1: To study the profile of the gut microbiome during intestinal tumor initiation.
Hypothesis 1.1: The microbiome profile of ApcMin/+ mice will exhibit a higher percentage
of Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to WT mice
at initiation of tumor development. The overall microbial diversity will be lower in ApcMin/+
mice as compared to their WT counterparts.
AIM 1.2: To study the profile of the gut microbiome during the progression of intestinal
tumor development.
Hypothesis 1.2: The microbiome profile of ApcMin/+ mice will exhibit a higher percentage
of Firmicutes bacteria and a lower percentage of Bacteroidetes as compared to their WT
counterparts during tumor progression. Firmicutes population will be higher during later
stages of tumorigenesis as compared to initial stages of tumorigenesis. Also, the microbial
diversity values will be lower in ApcMin/+ mice during tumor progression as compared to
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WT mice, and within ApcMin/+ mice at later stages of tumor development as compared to
their initial stages of tumorigenesis.

AIM 2: To determine if gut microbiome manipulation can regulate the ApcMin/+ mouse
health and tumorigenesis.
Rationale: The mucus layer tends to thickness with increased diversity of the microbiota
(Jakobsson, et al., 2015). Our preliminary data from a study on chronic inflammationinduced colon cancer using APNKO mice suggested that the gut microbiota changes in a
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as
compared to others (such as Bacteroidetes). It has not been studied yet as to whether there
is a relation between the altered percentages of especially the Firmicutes and Bacteroidetes
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that
the mucus layer provides a source of nutritional carbon and therefore energy to some of
the intestinal flora that are able to lyse the glycans present in the mucus, making the interrelationship between the gut bacteria and the mucus layer really important (H. Li et al.,
2015). Also, the metabolites produced by these microbes also influence the differentiation
and function of the epithelial and immune cells in the intestinal mucosa (Kato, et al., 2014;
Shan, et al., 2013). The regulation of the mucin gene expression as well as mucus
production have been shown to be two levels at which the gut microbial community may
modulate mucins (Comelli, et al., 2008). Our recent study (Kaur, et al., 2015) also
suggested that a reduction in the secretory mucin profile is associated with an inflammatory
phenotype of the gut (Figure 4). Therefore, the present aim will be directed at knowing the
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mucus-producing phenotypes of the cells lining the gut of the experimental animals in
relation to the changing profiles of the gut microbiota.
Hypothesis: Manipulation of the gut microbiota will lead to a decrease in gut health and
an increase in tumor number and size in the ApcMin/+ mouse. Furthermore, manipulation of
the gut microbiota will decrease goblet cell number in the intestine and colon.
AIM 2.1: To determine if manipulation of gut microbiome through antibiotic
administration affects disease prognosis in the ApcMin/+ mouse.
Hypothesis 2.1: The manipulation of gut microbiome by externally administered
antibiotics will lead to a worsening of disease prognosis in the experimental mice.
AIM 2.2: To determine if manipulation of gut microbiome through antibiotic
administration affects tumor number and size in the ApcMin/+ mouse.
Hypothesis 2.2: The manipulation of the gut microbiome by externally administered
antibiotics will lead to an increase in tumor number and size in ApcMin/+ mice.
AIM 2.3: To determine if gut microbiome manipulation effects goblet cell numbers in
small intestine and colon of ApcMin/+ mice as compared to WT mice.
Hypothesis 2.3: The manipulation of the gut microbiome by externally administered
antibiotics will lead to a reduction in goblet cell numbers in the intestine and colon of
ApcMin/+ mice.
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AIM 3: To determine if the relative abundance of Bacteroidetes and Fimicutes
bacterial populations is associated with intestinal and systemic inflammation in the
ApcMin/+ mouse.
Rationale: The induction of cancer in the gut by chronic inflammation has always
indicated towards the importance of underlying altered inflammatory processes (Wang &
Zhang, 2015). Different agents that have been documented to be effective against tumors
and cancers are the agents that function by downregulating important inflammatory
pathways and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction
of macrophage infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael,
2011; Murphy, Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999). It has also
been shown that the intestinal commensal bacteria plays a role in the development of gut
microenvironmental immune system comprising both the humoral and cellular components
and maintains the protective steady state immune function throughout life (Cebra, 1999;
Talham, et al., 1999). It may be more appropriate to say that any alteration in comparative
numbers of certain bacteria often lead to upregulation or downregulation of certain
inflammatory pathways. The systemic release of microbial products as a result of the
manipulation of the gut epithelium invokes an IL-23 response and a further IL-17 response
in order to neutralize further invasion by the microbes, and the process is brought about by
the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). The bacteria especially promotes
IL-17 cytokine in the small intestine which is the primary site of its attachment and survival
(Omenetti & Pizarro, 2015). These Th17 cells may become autoreactive in case of
intestinal epithelium insult. The bacteria Bacteroides fragilis from the Bacteroidetes
phylum leads to an increase in the production of IL-10 cytokine (Omenetti & Pizarro,

133

2015), whereas its strains have been implicated in the production of the pro-inflammatory
cytokine IL-17-dependent inflammation-related colon cancer (W. Wu, et al., 2015).
Inflammation, which is an integral part of tumorigenesis should therefore, may strongly be
correlated with a reduced bacterial diversity or numbers.
Hypothesis: An increase in the population of Firmicutes bacteria and/or a reduction in the
population of Bacteroidetes will lead to a higher inflammatory response in both the
intestinal tissue and systemic circulation.
AIM 3.1: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate intestinal tissue inflammation in the ApcMin/+ mouse.
Hypothesis 3.1: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations will increase the inflammatory cellular infiltration into the mucosa of the
intestinal tissue of the experimental mice.
AIM 3.2: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate intestine-secreted IL-1β, IL-17 and TNF-α in ApcMin/+ mice.
Hypothesis 3.2: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations will increase the intestine-secreted IL-1β, IL-17 and TNF-α levels in the
experimental mice.
AIM 3.3: To examine if the relative abundance of Bacteroidetes and Firmicutes
populations regulate systemic levels of cytokines IL-1β, IL-17 and TNF-α in ApcMin/+ mice.
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Hypothesis 3.3: An increase in Firmicutes and/or a reduction in Bacteroidetes bacterial
populations will increase systemic levels of IL-1β, IL-17 and TNF-α cytokines in the
experimental mice.
Limitations and Pitfalls:
1. The ApcMin/+ mouse model is different from the DSS-DMH chronic inflammationinduced cancer model (preliminary data). Therefore, microbiome profile of the ApcMin/+
model may be different from that of the DSS-DMH model of chronic inflammationinduced cancer model.
2. The microbiome profiles to be studied will be obtained from the fecal samples and will
be assumed to represent the bacterial repertoire of both small intestine and colon of the
experimental animals. Microbiome of the small intestine may be different from that of the
colon.
3. The effects of antibiotic administration on goblet cell production and inflammatory index
in the ApcMin/+ mouse model may be very different from those seen as a result of a single
bout of inflammation in the DSS-induced colitis model (preliminary data).
4. The ApcMin/+ mouse model is majorly an intestinal mouse model and most of the polyps
are seen in the small intestine. Thus, changes in goblet cell expression and inflammatory
index may be significant only in the small intestine of the experimental mice.
5. Administration of antibiotics to the experimental animals may lead to an increase in
intestine-secreted pro-inflammatory cytokines due erosion of the epithelial layer but may
not necessarily change them systemically.
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6. The study has a small sample size which may lead to lesser significant values of the
results that will be obtained from the study.

Working model

The central idea of the present study is to study the role of gut microbiota (bacterial) in
tumorigenesis, mucus producing phenotype and inflammation. In order to study this, we
will be using the ApcMin/+ model of intestinal cancer. The ApcMin/+ mouse model is raised
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from the C57BL/6 background where a point mutation on codon 850 of the Apc
(Adenomatous Polyposis Coli) gene leads to spontaneous development of polyps
(adenomas) in the intestinal mucosa (Zhang, et al., 2015). The mutation is responsible for
the production of a truncated APC protein (2843 amino acids) that lacks its C-terminal
domains. The protein functions to downregulate the Wnt signaling pathway by binding to
and promoting the destruction of the β-catenin protein. It has been shown that altered
interactions between the gut microbiota and colonic mucosa precede polyposis in the
ApcMin/+ mouse (Son, et al., 2015). Using the basis of an altered gut microbiota preceding
polyposis, we are trying to delve further into the processes that are hampered by alterations
in the gut microbiota, which can be used to elucidate the ways in which the gut microbiota
affects tumorigenesis.
The first aim of the study will be directed towards examining the composition of
gut microbiome during tumor initiation and development in ApcMin/+ mouse. This aim will
act as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of
tumorigenesis. Previous studies have demonstrated an alteration in gut microbiota to be
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even
immune system. Conditions such as Crohn’s disease and obesity have implicated gut
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The
characterization of the gut microbiome in the experimental ApcMin/+ mice will help define
the abundance of different bacterial species in the gut and their relative diversity values
during the initiation and progression of tumorigenesis.
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The second aim of the study will be directed towards elucidating the role of an
altered microbiome on pathology of the experimental animals. Antibiotics will be
administered to experimental mice in order to perturb the gut microbiota during the initial
and progressive stages of tumorigenesis. The use of antibiotics not only help get rid of
pathogenic bacteria but also deplete related micro-organisms, which fail to return to normal
levels even long after the antibiotic usage subsides (Cresci & Bawden, 2015). This aim will
thus help in elucidating the effect of alterations in microbiome in terms of their abundance
and diversity on the disease condition of the animals. This aim will also be directed towards
knowing if the tumor numbers and size are related to the microbiome and its alterations.
The third part of this aim will elucidate the effects of altered gut microbiome on expression
of goblet cells in the intestine and colon of mice. Our previous study (Saxena, et al., 2013)
has demonstrated that a reduction in goblet cell numbers leads to worsened disease
pathology and reduced protection against chronic inflammation-induced colon cancer. A
reduction in the number of mucus-producing goblet cells may also be altered in the ApcMin/+
model and further worsen the disease state once they are administered antibiotics.
The third aim of the present study will demonstrate the effects of an altered
microbiome on the inflammatory status of the experimental animals. Inflammation is an
important route through which alterations in gut microbiota affect the overall milieu of
inflammatory processes closely associated with the gut. The inflammatory response, along
with being systemic, has also been demonstrated to occur at a more localized level such as
the alterations in gut microbiota leading to increased levels of pro-inflammatory cytokines
such as IL-1β and TNF-α (Singh, et al., 2015). In the first part of aim 3 we will study the
effects of a changed microbiome on tissue-localized inflammation and infiltration
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occurring at the level of intestinal mucosa. The second part of the aim will help study the
effects of microbiome manipulation on intestine-secreted pro-inflammatory cytokines.
Whether the inflammatory effect is systemic or not, will be elucidated through the third
part of this aim where systemic levels of pro-inflammatory cytokines will be measured.

CHAPTER 2
Review of Literature
The ApcMin/+ mouse model
The ApcMin/+ mouse model is widely used by researchers to study gut inflammation and
cancer. The ApcMin/+ mouse model is raised from the C57BL/6 background where a point
mutation on codon 850 of the Apc (Adenomatous Polyposis Coli) gene leads to
spontaneous development of polyps (adenomas) in the intestinal mucosa (Zhang, et al.,
2015). The mutation is responsible for the production of a truncated APC protein (2843
amino acids) that lacks its C-terminal domains. The protein functions to downregulate the
Wnt signaling pathway by binding to and promoting the destruction of the β-catenin
protein. An altered APC protein thus leads to, apart from the development of intestinal
polyps, dysregulation of processes like cell adhesion, cell migration, chromosome
segregation and stability (McCart, et al., 2008).
The ApcMin/+ mouse model represents the human cancer syndrome called the
Familial Adenomatous Polyposis (FAP) where the human intestine may contain several
thousand adenomas by the age of 20-30 years, which corresponds to ~4-6 weeks in mouse.
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The ApcMin/+ mouse exhibits more than 50 tumors along the entire length of the intestine
and rarely live past the age of 21-22 weeks (Shoemaker, et al., 1997), which corresponds
to ~60 years of age in humans. Since all intestinal tumors in B6 Min/+ mice are benign
adenomas, the premature death of these animals is associated with secondary effects of
tumor growth, including severe, chronic anemia and intestinal blockage (Shoemaker, et al.,
1995).

The Gut Microbiome
The gut microbiome is an integral and an important symbiotic system present in the gut,
which comprises of bacteria, archaea, fungi and viruses residing in the gastrointestinal tract
throughout its length. The gut bacteria itself comprises a major percentage of the total gut
microbiome, where its numbers are in trillions. While the stomach and duodenum contain
about 101 to 102 Colony Forming Units (CFU) per mL of bacterial forms, the jejunum and
ileum comprise 104 to 108, and the colon has 1010 to 1012 CFU/mL of bacteria (Cresci &
Bawden, 2015). The microbiome acts advantageous for the gut such that it regulates gut
epithelial and endocrine cellular structure (Uribe, et al., 1994). The commensal bacterium
B. thetaiotaomicron VPI-5482, for example, which is a member of the gut flora, has been
linked to the functional processes of the gut such as nutrition absorption, mucosal barrier
function, metabolism, angiogenesis and postnatal intestinal maturation (Hooper & Gordon,
2001; Hooper, et al., 2001).
Previously, many studies have demonstrated an alteration in gut microbiota to be
linked to a variety of conditions including diabetes, arthritis, colitis and cancer and even
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immune system. Conditions such as Crohn’s disease and obesity have implicated gut
bacterial dysbiosis in pathogenesis (Chan, et al., 2015; Mai, et al., 2007). The highest
bacterial load is found in the distal small intestinal tract and colon - areas commonly found
to be associated with disease conditions (Hooper, et al., 2002; Kanauchi, et al., 2003). It
was not clear if the bacterial dysbiosis is a cause or consequence of the disease until
recently when it was shown that alterations in gut microbiome precede polyposis in the
ApcMin/+ mouse (Son, et al., 2015). An altered gut microbiome can cause inflammation
ranging from acute bouts to chronically inflamed gut. An altered microbiome, which shifts
from symbiotic to a more inflammation-inducing phenotype, leads to a vicious cycle of
erosion of the gut epithelial lining that, in turn, leads to more and more inflammatory
processes taking place inside the gut microenvironment (Saxena, et al., 2012; Zhang, et al.,
2015). A need to address and characterize host-microbe relations has been emphasized in
recent years in order to elucidate the processes and factors involved in the relationship
between the gut microbiome and inflammation and related tumorigenesis.
The intestinal epithelial lining has a strong relationship to the gut bacteria. The
bacterial flora of the intestine helps in digesting the food (especially carbohydrates) that
cannot be digested by the mammalian gut, and in turn, the intestinal epithelial cells
metabolize the short-chain fatty acids that result from the bacterial fermentation of the
undigested carbohydrates and use them as an energy source (Abreu, 2010).
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Antibiotic usage, gut microbiome and inflammation
Antibiotic treatments that are usually used against digestive tract infections not only target
the pathogenic microbes but also the host-interactive useful microbes. It is already known
that the use of antibiotics, especially broad spectrum, not only help get rid of pathogenic
bacteria but also deplete related micro-organisms, which fail to return to normal levels even
long after the antibiotic usage subsides (Cresci & Bawden, 2015). Microbial diversity also
is seen to be reduced in the gut following antibiotic treatment which exerts detrimental
effects (Lofmark, et al., 2006).
Antibiotic usage can severely and permanently affect 30% of the microbial
population (Dethlefsen & Relman, 2011). Once the antibiotic treatment is stopped, and
some resilient bacteria repopulate the gut, the final state is never a complete replacement
of the initial state (Francino, 2015). Any early antibiotic treatment in humans reduces the
overall diversity of the microbiota populations inside the gut which leads a disbalance of
the inflammatory molecules in the body. The disbalance between the Th1 and Th2
paradigm was at first thought to be the main culprit in bringing out the inflammatory effects
of the microbiota dysbalance. An increased Th1 activation was linked to harmful
inflammatory changes (Akdis & Akdis, 2009; Oboki, et al., 2008). However recently,
alterations in the gut microbiota have been linked to a dysregulation of the regulatory T
cell paradigm and their associated cytokines (Shen, et al., 2014), where the regulation of
this immunological pathway depends on the relationship between the gut microbiota and
the immune system. Different cocktails of antibiotics administered to mice have led to an
upregulation of either the Th2 or a Th17 response (Atarashi & Honda, 2011; Dimmitt, et
al., 2010), indicating that an alteration in the gut microbiota may favor one pathway and
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downregulate another inflammatory pathway. How the microbiota changes in the first
place and then a subsequent change occurs in the inflammatory pathways during
spontaneous tumorigenesis is a question that the present study will be aiming to answer via
studying different stages of tumorigenesis.
Inflammation is an important route through which alterations in gut microbiota
affect the overall milieu of inflammatory processes closely associated with the gut. Gut
microbiota manipulation through antibiotic treatment has been shown to cause a decrease
in the expression of the Muc2 protein, a major component of the intestinal mucus layer
(Dimmitt, et al., 2010). A thinning of the protective mucus layer leads to a direct contact
between the gut lining and the gut bacteria residing in the lumen, thereby triggering innate
immune responses and inflammation (Francino, 2015). The inflammatory response, along
with being systemic, also occurs at a more localized level such as the alterations in gut
microbiota leading to increased levels of pro-inflammatory cytokines such as IL-1β and
TNF-α (Vijay-Kumar, et al., 2010).
For the completion of aims 2 and 3, antibiotics will administered to the treatment
group of mice in three sets: 1). One cycle of antibiotic administration starting at 6 weeks
of age for 10 days and sacrifice at 8 weeks; 2). Two cycles of antibiotic administration
starting at 6 weeks and 10 weeks and sacrifice at 12 weeks; and 3). Three cycles of
antibiotic administration starting at 6, 10 and 14 weeks of age and sacrifice at 16 weeks.
Antibiotic administration at 6 weeks of age will signify the manipulation of gut microbiome
at the onset of tumorigenesis. This stage of tumorigenesis is marked by a gradual increase
in the number of polyps in the small intestine (Puppa, et al., 2011). Antibiotic
administration at 6 and 10 weeks of age will help define effects of microbiome altered at
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the beginning of tumorigenesis (6 weeks) and then at the middle of the life span of
experimental mice which is marked by progression of tumor development resulting in more
pronounced symptoms of anemia and intestinal blockage. While the polyp number reaches
a plateau, they only increase in size during this stage and the animals continue to lose body
weight (Puppa, et al., 2011). Antibiotic treatment at 6, 10 and 14 weeks will represent the
alterations in microbiome throughout the processes initiation of tumorigenesis. This stage
is marked by severe inflammation, continuation of tumor size and maximum weight loss
(Puppa, et al., 2011).

Impact of antibiotics
Although antibiotics are used against pathogenic microbes, their usage affects other
microbial members of the community as well. The effects that are established as a result of
an altered microbiome can be long-lasting even after the antibiotic treatment has subsided
(Jakobsson, et al., 2015; Jernberg, et al., 2007). While the more resilient bacteria are
successful at returning to their pre-treatment levels, others are lost indefinitely (Willing, et
al., 2011). Moreover, the occurrence of co-dependence between members of the
community based on differential metabolite production and utilization pathways leads to
perturbation of members that are not necessarily directly targeted by the antibiotic.
The direct and indirect effects of the antibiotics are brought about at different levels
and ways. The indirect effects are brought about by the changed gut microbiota. A change
in the bacterial population is known to cause a change in the downstream signaling by the
Pattern Recognition Receptors (PPRs) which help maintain epithelial integrity and repair
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process, while change in some bacterial populations that bind to Toll-like receptors, such
as TLR4, are linked to an altered innate immune defenses (Willing, et al., 2011). A reduced
production of short-chain fatty acids (SCFAs) is also a common feature of human
metabolic profiles after antibiotic treatment (Romick-Rosendale, et al., 2009; Yap, et al.,
2008). Changes in bacterial populations also affects differentiation of certain immune
system molecules such as IL-17 and often lead to a dysregulation of the immune system
(Ivanov, et al., 2009).
More direct effects include undesirable inflammation of the gut such as
gastroenteritis (Barthel, et al., 2003) and even dermatitis (J. Watanabe, et al., 2010).
Intestinal mucus layer
The gut lining is folded into tubular invaginations called the villi in the intestine and crypts
(of Leiberkuhn) in the colon. The gut lining is protected from the lumen microenvironment
by a single-cell layer comprising of absorptive enterocytes (which make most of the
epithelial cells), mucus-producing goblet cells, hormone-producing enteroendocrine cells
and Paneth cells that produce anti-microbial products in the gut (Abreu, 2010). The four
types of the cells line the single-celled layer of the gut that faces the lumen. All the four
types of cell arise from the pluripotent stem cells that lie at the base of the crypts. The
differentiated cells that arise from the stem cells of the crypts slowly and continuously rise
towards the crypt apex from where the single-celled layer is regularly shed and renewed to
maintain a healthy gut, also providing the crypt with a feature of polarity.
The mucus in the small and large intestine is secreted by the goblet cells. It forms
the first line of defense between the gut lumen microenvironment and the underlying
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epithelial layer and the submucosa. The mucin proteins in the gut mainly comprise of the
MUC2 and MUC5AC proteins. They have properties of forming gel like coating onto the
gut lumen once getting hydrated and form highly glycosylated proteins that are resistant to
the digestive environment of the gut (Koboziev, et al., 2014). Changes in goblet cell
function, secretion of mucins into the lumen and composition of this mucus layer are shown
to be altered by an altered microbiome (Deplancke & Gaskins, 2001). The mucus layer
provides a balanced ecosystem for the resident and as well as pathogenic bacteria in the
intestinal lumen by acting as a source of nutrition, thus indicating a homeostatic balance
between the host gut microenvironment and the microbiome associated with it (Aristoteli
& Willcox, 2003). An alteration in one of them may render the other dysfunctional. It is
also said that the resident bacteria may inhibit the adherence of pathogenic bacteria to the
intestinal epithelial cells by increasing the production of intestinal mucus (Mack, et al.,
2003; Mack, et al., 1999; Smirnova, et al., 2003).

Mucus and gut microbiome
It has been shown that the mucus layer tends to thickness with increased diversity of the
microbiota (Jakobsson, et al., 2015). The mucus layer provides a source of nutritional
carbon and therefore energy to some of the intestinal flora that are able to lyse the glycans
present in the mucus, making the inter-relationship between the gut bacteria and the mucus
layer really important (H. Li, et al., 2015). Also, the metabolites produced by these
microbes also influence the differentiation and function of the epithelial and immune cells
in the intestinal mucosa (Kato, et al., 2014; Shan, et al., 2013). Our recent study (Kaur, et
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al., 2015) also suggested that a reduction in the secretory mucin profile is associated with
an inflammatory phenotype of the gut. Inflammation, which is an integral part of
tumorigenesis should therefore, may strongly be correlated with a reduced bacterial
diversity or numbers. Moreover, both Gram-positive and Gram-negative bacteria are
known to enhance the intestinal mucin expression (Dohrman, et al., 1998). The regulation
of the mucin gene expression as well as mucus production have been shown to be two
levels at which the gut microbial community may modulate mucins (Comelli, et al., 2008).
Gut microbiota manipulation through antibiotic treatment has been shown to cause a
decrease in the expression of the Muc2 protein, a major component of the intestinal mucus
layer (Wlodarska, et al., 2011). A thinning of the protective mucus layer leads to a direct
contact between the gut lining and the gut bacteria residing in the lumen, thereby triggering
innate immune responses and inflammation (Francino, 2015).

Gut microbiome and Apc-min
Studies that work at elucidating the role of gut microbes in disease models, have been
limited, especially due to the fact that most of the important gut bacteria are difficult to
grow in a laboratory setting making them unavailable for studying unless mammalian
models are used. However, there are evidences that the manipulation of the gut microbiome
through diet modulations, can alter the disease conditions such as those in Crohn’s disease
and Inflammatory Bowel Disease (Mai, et al., 2007). Studies that use the ApcMin/+ mouse
model for studying gut diseases and their association with microbiota often report
significant changes in microbiome profiles of the large intestine, but also report that
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differences in the polyps is only significant in the small intestine (Mai, et al., 2007) The
detrimental effects are also brought about via loss of certain colonizing bacterial species
that are dependent on other colonizers for processes such as nutritional interactions and
removal of secondary metabolites and toxic waste products (Belenguer, et al., 2006), or
through loss of useful co-evolved processes brought about by the host-microbial codependence (Atarashi & Honda, 2011; Ferreira, et al., 2011). There are no studies that
study the gut microbiome with respect to gut inflammation and tumorigenesis in an
age/time- dependent manner. It has been seen that specific pathogen-free (SPF) ApcMin/+
exhibit a higher tumor load and anemia with a higher infiltration of inflammatory cells
specifically at advanced stages as compared to germ-free animals, indicating that a mere
modulation of gut microbiome profiles can abrogate the disease condition in the gut (Y.
Li, et al., 2012).

Gut microbiome, inflammatory cytokines and tumorigenesis
It is a fact that till date, one of the most effective class of chemopreventive agents is the
non-steroidal anti-inflammatory drugs (NSAIDs). The induction of cancer in the gut by
chronic inflammation has always indicated towards the importance of underlying altered
inflammatory processes (Zhang, et al., 2015). Different agents that have been documented
to be effective against tumors and cancers are the agents that function by downregulating
important inflammatory pathways and pro-inflammatory cytokines. Apart from the usual
NSAIDs that function by downregulating the metabolism of the arachidonic acid through
the Cyclooxygenase (COX) pathways agents such as curcumin and quercetin exert their
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chemopreventive effects through the downregulation of mRNA expression levels of proinflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of macrophage
infiltration (Y. Li, et al., 2012; Murphy, Davis, McClellan, & Carmichael, 2011; Murphy,
Davis, McClellan, Gordon, et al., 2011; Ritland, et al., 1999).
It has also been shown that the intestinal commensal bacteria plays a role in the
development of gut microenvironmental immune system comprising both the humoral and
cellular components and maintains the protective steady state immune function throughout
life (Cebra, 1999; Talham, et al., 1999). It may be more appropriate to say that any
alteration in the composition of the gut microbiome will lead to a dysfunctional immune
system.
Certain bacterial species such as B. thetaiotaomicron bacterium have been
associated with the attenuation of pro-inflammatory responses by reducing the levels of the
pro-inflammatory cytokine IL-8 (Zhao, et al., 2001).
Comparative numbers of certain bacteria often lead to upregulation or
downregulation of certain inflammatory pathways. The systemic release of microbial
products as a result of the manipulation of the gut epithelium invokes an IL-23 response
and a further IL-17 response in order to neutralize further invasion by the microbes, and
the process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014).
The bacteria especially promotes IL-17 cytokine in the small intestine which is the primary
site of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may
become autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides
fragilis from the Bacteroidetes phylum leads to an increase in the production of IL-10
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cytokine (Omenetti & Pizarro, 2015), whereas its strains have been implicated in the
production of the pro-inflammatory cytokine IL-17-dependent inflammation-related colon
cancer (W. Wu, et al., 2015).
It is widely accepted that inflammation contributes to the development of cancer
and inflammatory cells have been noted in and around tumors (Hanahan & Weinberg,
2011). A relationship between inflammation and intestinal neoplasia is supported by the
facts that inflammatory bowel disease predisposes patients to intestinal carcinomas and
that the anti-inflammatory drugs aspirin (Baron, et al., 2003), celecoxib (Bertagnolli, et al.,
2006), and rofecoxib (Bertagnolli, et al., 2006), all have proven efficacy in preventing
human colorectal adenoma development.
Adenoma formation has been shown to increase following adoptive transfer of proinflammatory lymphocytes (Rao, et al., 2006) and decreased after the adoptive transfer of
anti-inflammatory regulatory T-cells (Treg cells) (Erdman, et al., 2005). Apart from direct
effects of inflammatory cells, adenomas are also known to be impaired by the absence of
the molecule MyD88 which mediates the downstream inflammatory signaling as a
response to bacterial and viral products (Rakoff-Nahoum & Medzhitov, 2007). Proinflammatory pathways such as those involved with IL-17 secretion are associated with
many chronic inflammatory conditions such as asthma (Schnyder-Candrian, et al., 2006)
and inflammatory bowel disease (Yen, et al., 2006), along with colon carcinogenesis
(Langowski, et al., 2006). IL-17, especially, has been denoted as a marker and mediator of
tumor angiogenesis (Langowski, et al., 2006). Over-expression of pro-inflammatory
factors such as IL-6, MCP-1, NF-ᴋB and IL-8 can aggravate tumors (Wang & Zhang,
2015).
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In the context of the ApcMin/+ mouse model, the mutual interaction of macrophages
with cancer cells enhances production of inflammatory cytokines such as IL-1, IL-6 and
TNF-α that transform the tumor microenvironment so that it favors the survival, growth
and motility of cancer cells. Reduction in pro-inflammatory molecules such as MCP-1
leads to a decrease in the total polyp number and size in the ApcMin/+ mouse along with
downregulating inflammatory processes in tumor tissues and surrounding tumor
microenvironment (McClellan, Davis, Steiner, Day, et al., 2012). An elevation in the
intestinal inflammatory cytokine (MCP-1, IL-1β, IL-6 and TNF-α) response occurs at 12
weeks of age as a result of the rapid increase in polyp number, which are further elevated
with increase in polyp size. A similar study by McClellan et al (2012) (McClellan, Davis,
Steiner, Enos, et al., 2012) shows an increased mRNA expression of MCP-1, IL-1b, IL-6
and TNF-α that is evident at 12 weeks of age and is consistent with the increase in polyp
number that occurs at this time. After the age of 12 weeks which is associated with the
largest number of small polyps, the inflammatory response continues to increase while the
number of polyps remain constant which indicates that the inflammatory response after 12
weeks could largely be driven by polyp size. However, it is still unclear whether the
changes in polyp number and size that occurs in this model is a result of the elevated
inflammatory response or vice versa (McClellan, Davis, Steiner, Enos, et al., 2012).

16S rRNA gene profiling and sequencing
The 16S rRNA gene method is one of the earliest and most widely used methods used for
phylogenetic, taxonomic and bioinformatics analyses. It targets the 16S rRNA bacterial
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genes to know diversity or similarities in biological samples. The 16S rRNA gene provides
many advantages in microbiome analyses including its universal distribution in bacterial
species, relative stability in evolution and ideal size (1500 bp). Consisting of both constant
and variable regions, the 16S gene is easy to amplify used broad-range primers used against
regions flanking its variable regions (Sankar, et al., 2015).

Statistical Power of the study
The microbiome analysis in our study will be done using the fecal samples from
experimental mice. A 16S rRNA gene sequencing technique will be used to study the gut
microbial populations in the animals. The sample size for the study is 4. Some of the
previous studies that have been directed towards similar microbial analyses have used
similar samples sizes. Russell et al (2012) (Russell, et al., 2012) used n = 3-5 to study
changes in the gut microbial communities in C57BL/6 mice following antibiotic treatment
at neonatal and adult stages of life. The results showed significant reductions in the overall
bacterial diversity and phyla abundance in antibiotic-treated mice as compared to control
mice (p value<0.05). Oh et al (2016) (Oh, et al., 2016) used a sample size of 5 mice per
group in order to show significant differences in bacterial load and diminished rDNA in
antibiotic-treated mouse fecal samples as compared to their control counterparts. Similar
studies have used n = 4-6 mice per group in order to show Significant (p value<0.01)
changes in gut microbial constituents as a result of administration of the antibiotic
enrofloxacin with an increase in type-2 cytokines has been shown in a study that used 4 to
6 (n) mice per group (Strzepa, et al., 2016).
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PRELIMINARY DATA
Preliminary data for Aim 1:
Chronic inflammation and colon cancer was induced in Dextran Sodium Sulphate (DSS) +
DMH treatment group in both APNKO (n=5) and WT (n=5) mice by administering DSS
dissolved in their drinking water for five days followed by five days of regular drinking
water along with administering a single injection of DMH intraperitoneally once a week
for 12 weeks at a concentration of 20mg/kg body weight of mice at the beginning of DSS
treatment. Fecal samples were collected at the time of sacrifice and were analyzed by
sequencing the V3 variable region of bacterial 16S rRNA gene to profile the composition
of the microbiome (Figure 1).
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Figure 1. Bacterial phylum profiles are altered during cancer development. The figure
illustrates distribution of different bacterial phyla (percentages) in colons tissues of WT
(C57BL/6) and APNKO mice belonging to control and DSS+DMH treatment groups.

Preliminary data for Aim 2:
Clinical score which is a summation of weight loss, diarrhea and fecal hemoccult was
determined during the length of the study thrice a week till the date of sacrifice (day 153).
We found a significant increase in the clinical score of the APNKO mice on day 30 and
then at day 67 which remained significantly high till the end of the study as compared to
WT mice given the same treatment (Figure 2).
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Figure 2. Clinical score of increases during tumor development. Clinical score for
DSS+DMH treatment was plotted against different time points of the study. The score was
calculated out of a total of twelve points; four points each for the observations of weight
loss, diarrhea and hemoccult. Two-way repeated measure analysis of variance (ANOVA)
was applied to calculate the significant difference between the clinical score for APNKO
and WT mice throughout the length of the study. **pb0.05, #pb0.001, *pb0.03.
The data shown in figures 1 and 2 demonstrate that there may be a correlation between the
abundance of Firmicutes bacterial phylum and clinical score such that an increased
abundance of Firmicutes may be associated with disease severity in colon cancer.
Mice were sacrificed on day 153 and the colon was excised and flushed with PBS. Colon
was cut open longitudinally and stained with 2% methylene blue to count the tumor number
and tumor area. Significant increase in the tumor number and area was found in the
APNKO mice as compared to the WT mice (Figure 3).

155

Figure 3. Tumor development in APNKO and WT mice treated with DSS+DMH. (A)
Average number of tumors counted per mice per group. (B) Average tumor area in mm2
counted for each mouse per group plotted in the order of their severity. One-way ANOVA
was used to calculate significant difference between APNKO and WT mice. *p<0.05.
The data shown in figures 1 and 3 demonstrate that there may also be a correlation between
the abundance of Firmicutes bacterial phylum and tumor number and size such that an
increased abundance of Firmicutes may be associated with a higher tumor load in colon
cancer.
Mice colon were harvested in 2 mm2 sections and were embedded in embedded in paraffin.
5 µm sections were cut using a microtome. Standard deparaffinization procedure was
followed using xylene and gradation of ethanol. Alcian blue solution (1 %) of pH 2.5 in 3
% acetic acid and nuclear fast red in aluminum sulfate was prepared. Tissues were stained
with Alcian blue and counterstained with nuclear fast red solution. Goblet to epithelial cell
ratio was counted per crypt with ten crypts per section and five sections per group (Figure
4). The staining revealed a reduction in the number of mucus-producing goblet cells in the
DSS+DMH group both in APNKO and WT groups.
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Figure 4. Goblet to epithelial cell ratio is decreased in colon cancer. Descending colon, 2
mm2 sections of the mice stained with Alcian blue dye representing goblet cells (blue) in
APNKO and WT groups belonging to Control and DSS+DMH groups.
The data shown in figures 1 and 4 may indicate a correlation between the abundance of
Firmicutes bacterial phylum and a decreased expression of mucus-producing phenotype of
the cells lining the gut epithelium which renders a reduced protection from epithelial insult
and inflammation during cancer.
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Preliminary data for Aim 3:
Mice colon paraffinized sections were cut using a microtome into 5 µm thickness. Standard
deparaffinization procedure was followed using xylene and gradation of ethanol.
Hematoxylin and Eosin staining was performed to highlight the general tissue structure
(Figure 5). The DSS+DMH group revealed increased cellular infiltration into the colonic
mucosal layers indicative of an increased inflammatory index.

Figure 5. Inflammation and infiltration of colon epithelium. H&E stained sections of the
descending colon of APNKO and WT mice in DSS+DMH group with 20X magnification
(scale bar=120 μm).
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RESEARCH DESIGN AND METHODS
Overall Research Design: The overall purpose of the present study is to elucidate the role
of alteration in the gut microbiome on disease severity in an intestinal cancer model of
mouse. The study will firstly comprise of a preliminary data on characterizing the
alterations in the gut microbiome of the ApcMin/+ mouse. An external manipulation of the
microbiome with the help of an antibiotic cocktail will then be used in order to control the
microbiome manipulation cycles and accurately understanding the role of the microbial
alteration on health, tumorigenesis, mucus production and inflammation. So far, no study
has demonstrated these effects brought about by an altered gut microbiome throughout the
development of tumor.
The first aim of the study will be directed towards examining the composition of
gut microbiome during tumor initiation and development in ApcMin/+ mouse. This aim will
act as preliminary to aims 2 and 3 by characterizing and thereby defining the alterations
occurring in the microbiome of ApcMin/+ mouse during initiation and progression of
tumorigenesis. The characterization of the gut microbiome in the experimental ApcMin/+
mice will help define the abundance of different bacterial species in the gut and their
relative diversity values during the initiation and progression of tumorigenesis.
The second aim of the study will be directed towards elucidating the role of a
manipulated microbiome on pathology of the experimental animals. Antibiotics will be
administered to experimental mice in order to perturb the gut microbiota during the initial
and progressive stages of tumorigenesis. This aim will thus help in elucidating the effect
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of alterations in microbiome in terms of their abundance and diversity on the disease
condition, tumorigenesis and goblet cell expression levels in the animals.
The third aim of the present study will demonstrate the effects of microbial
manipulation on the inflammatory status of the experimental animals. In the first part of
aim 3 we will study the effects of an altered microbiome on tissue-localized inflammation
and infiltration occurring at the level of intestinal mucosa. The second part of the aim will
help study the effects of microbiome alteration on intestine-secreted pro-inflammatory
cytokines. Whether the inflammatory effect is systemic or not, will be elucidated through
the third part of this aim where systemic levels of pro-inflammatory cytokines will be
measured.

A timeline for the present study is provided below:

Figure 6. Study timeline and time points.

AIM 1: To examine the composition of gut microbiome during tumor initiation and
development in ApcMin/+ mouse.
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Rationale: An altered gut microbiome can cause inflammation ranging from acute bouts
to chronically inflamed gut. An altered microbiome, which shifts from symbiotic to a more
inflammation-inducing phenotype, leads to a vicious cycle of erosion of the gut epithelial
lining that, in turn, leads to more and more inflammatory processes taking place inside the
gut microenvironment (Saxena, et al., 2012; Zhang, et al., 2015). Our previous study on
chronic inflammation-induced colon cancer in the APNKO (Adiponectin-knockout) mice
demonstrated microbiota profiles that were clearly altered during tumorigenesis. The
alterations mainly pertained to the altered percentages of the Firmicutes and Bacteroidetes
bacterial phyla during inflammation-induced tumorigenesis in the mice (Figure 1). As
opposed to externally administered chemically-induced tumorigenesis in mice, the
microbiota has not been studied with respect to a spontaneously induced tumorigenesis
such as that in the ApcMin/+ mouse. It was recently concluded that an alteration of gut
microbiome precedes polyposis in the ApcMin/+ mouse (Son, et al., 2015). Also, it has been
seen that specific pathogen-free (SPF) ApcMin/+ exhibit a higher tumor load and anemia with
a higher infiltration of inflammatory cells specifically at advanced stages as compared to
germ-free animals, indicating that a mere modulation of gut microbiome profiles can
abrogate the disease condition in the gut (Y. Li, et al., 2012). However, there are no studies
that study the gut microbiome with respect to gut inflammation and tumorigenesis in an
age/time- dependent manner. Therefore, the first aim of the present study will be directed
towards characterization of alterations of microbiome profiles from early to later stages of
tumorigenesis in an ApcMin/+ mouse model.
AIM 1.1: To study the gut microbiome profiles of ApcMin/+ mice during intestinal
tumor initiation.
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AIM 1.2: To study the gut microbiome profiles for ApcMin/+ mice during intestinal
tumor progression.
AIM 1.3: To study the gut microbiome profiles of ApcMin/+ mice during peak of
intestinal tumorigenesis.
Experimental Design Specific Aim 1: Aim 1 will study the composition of the gut
microbiome during initiation and development of tumorigenesis in ApcMin/+ mouse model.
Four weeks old male ApcMin/+ and C57BL/6 (WT) mice will be housed at the Animal
Resource Facility, USC. Food (Purina chow) and drinking water will be available to the
mice ad libidum under a 12:12 hour light-dark cycle and a low-stress environment (22oC,
50% humidity and low noise). Cumulative clinical scores will be obtained for each mouse
twice a week with a maximum clinical score of 12. The clinical score for each mouse will
be based on weight loss measurement, diarrhea and fecal hemoccult. The experimental
animals will be sacrificed at 8, 12 and 16 weeks as per figure 6, without any antibiotic
treatment, and microbiome profiles will be studied using fecal samples at each of the three
time points.
Animal Model and Handling: Four weeks old ApcMin/+ mice will be obtained from the
Jackson Laboratories and bred at the Animal Resource Facility at University of South
Carolina. Food (Purina chow) and drinking water will be available to the mice ad libidum
under a 12:12 hour light-dark cycle and a low-stress environment (22oC, 50% humidity
and low noise). All animal care followed institutional guidelines under a protocol approved
by the Institutional Animal Care and Use Committee at the University of South Carolina.
Cumulative clinical scores will be obtained for each mouse twice a week with a maximum
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clinical score of 12. The clinical score for each mouse will be based on weight loss
measurement, diarrhea and fecal hemoccult with a maximum score of 4 within each of the
three quantitative parameters. ApcMin/+ and WT mice will be randomLy assigned to three
groups (n=4): 1) 8 weeks; 2) 12 weeks; 3) 16 weeks.

Mice will be monitored throughout the course of study for weight loss, diarrhea and fecal
hemoccult. Mice will sacrificed at the three different time points by cervical dislocation.
Blood will be collected before sacrifice through retro-orbital puncture, centrifuged at
10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C. Small intestine
and colon will be excised and flushed clean with PBS. 2 mm2 colon tissue sections will be
fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed by
paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice
for microbiome analysis.

Material and methods:
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Clinical score
Clinical score will be measured for each mouse twice during each week of the study. Mice
will be sacrificed after the last clinical score measurement. Cumulative clinical scores will
be obtained for each mouse twice a week with a maximum clinical score of 12. The clinical
score for each mouse will be based on weight loss measurement, diarrhea and fecal
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the
three quantitative parameters. The clinical score will be calculated by the following
method:

Table 1. Clinical score measurement criteria
Tissue and serum collection
Mice will sacrificed at the three different time points by cervical dislocation. Blood will be
collected before sacrifice through retro-orbital puncture, centrifuged at 10,000 rpm for 15
minutes and serum will be isolated and stored at -20°C. Small intestine and colon will be
excised and flushed clean with PBS. 2 mm2 small intestine and colon tissue sections will
be fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed
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by paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice
for microbiome analysis.

16S rRNA-based Metagenomics
At sacrifice, fecal samples will be obtained from the experimental mice to perform bacterial
(luminal) microbiome analysis. Bacterial n16S rRNA gene amplification and sequencing
will be performed at the Alkek Center for Metagenomics and Microbiome Research,
Department of Molecular Virology and Microbiology, Baylor College of Medicine
(Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 region of the
bacterial 16 S rRNA gene will be performed using the Illumnia Miseq sequencer. The
consensus sequences obtained from the analysis will be mapped into Operational
Taxonomic Units (OTUs). Alpha- and beta-diversity values will be obtained based on the
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity
Index (richness and evenness) will be used to obtain the alpha diversity values. Weighted
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance)
will be performed to obtain the beta-diversity values for the experimental samples (He, et
al., 2016). Kruskal Wallis and Mann Whitney statistical analyses will be performed to
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calculate significance in diversity and relative abundance respectively, by comparing
different treatments and disease stages. A p value of less than 0.05 will be considered
significant.

Primary Outcomes:
Alpha diversity
The metagenomics Chao1 and Shannon indices will be used to measure the alpha diversity
values for different groups of experimental animals. Alpha diversity values will be used to
measure total species richness within the individual fecal samples (Weir et al., 2013).
Beta diversity
The metagenomics Unifract index will be used to measure the beta diversity values among
the different experimental groups. The beta diversity values will be used to measure the
degree of diversity among the different experimental groups and thus will give a measure
of difference in diversity between different groups (Weir, et al., 2013).
Relative abundance of different bacterial phyla
The relative abundance of different phyla will be plotted for each of the experimental
groups in order to characterize the dominance of one or more phyla during initiation and
development of tumorigenesis and under normal conditions.
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AIM 2: To determine if gut microbiome manipulation can regulate ApcMin/+ mouse
health and tumorigenesis.
Rationale: The mucus layer tends to thickness with increased diversity of the microbiota
(Jakobsson, et al., 2015). Our preliminary data from a study on chronic inflammationinduced colon cancer using APNKO mice suggested that the gut microbiota changes in a
way that favors an increased percentage of bacteria of certain phyla (here, Firmicutes) as
compared to others (such as Bacteroidetes). It is not been studied yet as to whether there is
a relation between the altered percentages of especially the Firmicutes and Bacteroidetes
phyla populations, and tumor number, tumor size and goblet cell numbers. It is known that
the mucus layer provides a source of nutritional carbon and therefore energy to some of
the intestinal flora that are able to lyse the glycans present in the mucus, making the interrelationship between the gut bacteria and the mucus layer really important (H. Li, et al.,
2015). Also, the metabolites produced by these microbes also influence the differentiation
and function of the epithelial and immune cells in the intestinal mucosa (Kato, et al., 2014).
The regulation of the mucin gene expression as well as mucus production have been shown
to be two levels at which the gut microbial community may modulate mucins (Comelli, et
al., 2008). Our previous study (Saxena, et al., 2013) also suggested that a reduction in the
secretory mucin profile is associated with an inflammatory phenotype of the gut (Figure
4). Therefore, the present aim will be directed at knowing the mucus-producing phenotypes
of the cells lining the gut of the experimental animals in relation to the changing profiles
of the gut microbiota.
AIM 2.1: To determine if gut microbiome manipulation effects intestinal tumor number
and size in small intestine and colon of ApcMin/+ mice.
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AIM 2.2: To determine if gut microbiome manipulation effects goblet cell numbers in
small intestine and colon of ApcMin/+ mice as compared to C57BL/6 mice.
AIM 2.3: To determine if gut microbiome manipulation leads to a differential
recolonization of Bacteroidetes and Firmicutes populations of bacteria ApcMin/+ mice as
compared to C57BL/6 mice.
Experimental Design Specific Aim 2: Aim 2 will study the effects of manipulation of the
gut microbiome primarily on health in terms of disease severity and tumorigenesis in terms
if tumor number and size. Secondarily, aim 2 will also be directed towards quantifying the
number of goblet cells in the small intestine and colon of the experimental animals.
The first part of aim 2 will be to study the role of manipulation of microbiota on
the health of the experimental animals. The gut health of the animals will be monitored by
clinical score which will be calculated in the same way as that in aim 1.
The second part of aim 2 will decipher the role of an altered microbiome via
administration of antibiotics to the animals, on tumor number and size throughout the
process of tumorigenesis.
The third part of aim 2 will be directed towards determining the role of microbiome
manipulation on the expression of mucus-producing goblet cells in the epithelium of small
intestine and colon of the experimental animals.
Aim 2 will provide a mechanistic way of deciphering the role of an altered
microbiome on three of the processes which define a disease state pertaining to the gut.
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Animal Model and Handling: 4 weeks old ApcMin/+ and C57BL/6 (WT) mice will be
obtained from Jackson Laboratories and bred in-house at the Animal Resource Facility,
University of South Carolina. Food (Purina chow) and drinking water will be available to
the mice ad libidum under a 12:12 hour light-dark cycle and a low-stress environment
(22oC, 50% humidity and low noise). The ApcMin/+ and C56BL/6 mice will be assigned to
the following groups:

WT-Control (no antibiotic)-8 weeks, WT-Antibiotic (ABT)-8

weeks, WT-Control-12 weeks, WT-ABT-12 weeks, WT-Control-16 weeks, WT-ABT-16
weeks, ApcMin/+-Control-8 weeks, ApcMin/+-ABT-8 weeks, ApcMin/+-Control-12 weeks,
ApcMin/+-ABT-12 weeks, ApcMin/+-Control-16 weeks and ApcMin/+-ABT-16 weeks. All
animal care will follow institutional guidelines under a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Carolina.
Cumulative clinical scores will be obtained for each mouse twice a week with a maximum
clinical score of 12. The clinical score for each mouse will be based on weight loss
measurement, diarrhea and fecal hemoccult with a maximum score of 4 within each of the
three quantitative parameters. The ApcMin/+ -Control animals to be used in aim 2 will be the
same as those used in aim 1.
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Mice will be monitored throughout the course of study for weight loss, diarrhea and fecal
hemoccult. Mice will sacrificed at the three different time points by cervical dislocation.
Blood will be collected before sacrifice through retro-orbital puncture, centrifuged at
10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C. Small intestine
and colon will be excised and flushed clean with PBS. 2 mm2 colon tissue sections will be
fixed in 10% formalin and after 24 hours will be replaced with 70% ethanol followed by
paraffin embedding and sectioning to obtain 5 µm thin sections on glass slides. 2 mm2
intestine and colon tissue sections will be incubated in RPMI medium at 37°C for 24 hours
followed by centrifugation at 2500 rpm for 15 minutes. Supernatant will be obtained and
stored at -20°C for tissue-secreted cytokine expression analyses. The rest of tissues will be
stored at -80oC for further usage. Fecal samples will be snap frozen at the time of sacrifice
for microbiome analysis.

Material and methods:
Antibiotic administration: An antibiotic mixture containing Vancomycin, Neomycin and
Streptomycin (each 1 mg/mL) will be administered to experimental mice under the
antibiotic treatment groups. While neomycin and streptomycin act against Gram-negative
bacteria, vancomycin is used against Gram-positive bacteria. The antibiotics mixture will
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be administered to the mice through drinking water starting at the 5th, 10th and 14th weeks
for 10 days followed by normal drinking water.

Clinical score: Clinical score will be measured for each mouse twice during each week of
the study. Mice will be sacrificed after the last clinical score measurement. Cumulative
clinical scores will be obtained for each mouse twice a week with a maximum clinical score
of 12. The clinical score for each mouse will be based on weight loss measurement,
diarrhea and fecal hemoccult (kit, BECKMAN COULTER) with a maximum score of 4
within each of the three quantitative parameters. Score for the weight loss is based on the
following published scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–
15% weight loss; 3 = 16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea
is as follows: 0 = well-formed pellets, 2 = pasty and semi-formed stools that do not adhere
to the anus, 4 = liquid stools that adhere to the anus. Detection of blood in the stools will
be determined using hemoccult kit (BECKMAN COULTER). The higher intensity of blue
color indicates greater bleeding. The followings are the score rates for the fecal hemoccult:
0 = no blood, 2 = positive hemoccult, 4 = gross bleeding. The total clinical score will be
the summation of the individual score of weight loss, diarrhea and fecal hemoccult. The
maximum score a mouse could get is 12.

Tissue and serum collection: Mice will sacrificed at the three different time points by
cervical dislocation. Blood will be collected before sacrifice through retro-orbital puncture,
centrifuged at 10,000 rpm for 15 minutes and serum will be isolated and stored at -20°C.
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Small intestine and colon will be excised and flushed clean with PBS. 2 mm2 small intestine
and colon tissue sections will be fixed in 10% formalin and after 24 hours will be replaced
with 70% ethanol followed by paraffin embedding and sectioning to obtain 5 µm thin
sections on glass slides. 2 mm2 intestine and colon tissue sections will be incubated in
RPMI medium at 37°C for 24 hours followed by centrifugation at 2500 rpm for 15 minutes.
Supernatant will be obtained and stored at -20°C for tissue-secreted cytokine expression
analyses. The rest of tissues will be stored at -80oC for further usage. Fecal samples will
be snap frozen at the time of sacrifice for microbiome analysis.

Tumor Number and Area: Small intestine and colon from the experimental animals will
be excised and flushed with PBS. Tumor number and area will be counted using 1% Methyl
Blue stain under the light microscope for all mice in different groups and significant
difference will be calculated.

Alcian Blue staining: Standard deparaffinization procedure will be followed using xylene
and gradations of ethanol. Alcian Blue dye solution for staining mucus-containing goblet
cells will be prepared by dissolving the dye powder (8GX) at 1% concentration in 3%
acetic acid solution and setting the pH at 2.5. Nuclear Fast Red solution for staining the
epithelial cells of the mucosa will be prepared at a final concentration of 0.1% dissolved in
5% aluminium sulfate solution. Tissues will firstly be stained with Alcian Blue and then
counterstained with Nuclear Fast Red solution. Goblet to epithelial cell ratio will be
counted per crypt with ten crypts per section and five sections per group.
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Statistical analysis: Two-way analysis of variance (ANOVA), Two-way repeated measure
ANOVA and One-way ANOVA will be used to analyze the data with Tukey post hocanalyses. A p<0.05 will be considered statistically significant. All the statistical analyses
will be done using SigmaStat 3.5 (SPSS, Chicago, IL).

PRIMARY OUTCOMES:
Clinical score
Clinical score will be measured for each mouse twice during each week of the study. Mice
will be sacrificed after the last clinical score measurement. Cumulative clinical scores will
be obtained for each mouse twice a week with a maximum clinical score of 12. The clinical
score for each mouse will be based on weight loss measurement, diarrhea and fecal
hemoccult (kit, BECKMAN COULTER) with a maximum score of 4 within each of the
three quantitative parameters. Score for the weight loss is based on the following published
scale where 0 = 0–5% weight loss; 1 = 6–10% weight loss; 2 = 11–15% weight loss; 3 =
16–20% weight loss; and 4 = >20% weight loss. Scoring of diarrhea is as follows: 0 = wellformed pellets, 2 = pasty and semi-formed stools that do not adhere to the anus, 4 = liquid
stools that adhere to the anus. Detection of blood in the stools will be determined using
hemoccult kit (BECKMAN COULTER). The higher intensity of blue color indicates
greater bleeding. The followings are the score rates for the fecal hemoccult: 0 = no blood,
2 = positive hemoccult, 4 = gross bleeding. The total clinical score will be the summation
of the individual score of weight loss, diarrhea and fecal hemoccult. The maximum score
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a mouse could get is 12. The clinical score will be studied as an effect due to the
perturbation of microbiome.
Tumor number and area
Small intestine and colon from the experimental animals will be excised and flushed with
PBS. Tumor number and area will be counted using 1% Methyl Blue stain under the light
microscope for all mice in different groups and significant difference will be calculated.
Tumor number and/or area will also be correlated with the manipulation of the microbiome.

Secondary outcomes:
Goblet cells
Goblet cells counted through Alcian Blue staining will form a secondary outcome of aim
2 in the present study. Since goblet cells form a mucus-producing phenotype of the gut
lining, their presence is associated with better prognosis of disease. A manipulation of
microbiome may work to reduce the numbers of goblet cells in small intestine and colon.

AIM 3: To determine if a change in relative abundance Bacteroidetes and Fimicutes
population regulate(s) systemic inflammation in ApcMin/+ mice.
Rationale: The induction of cancer in the gut by chronic inflammation has always
indicated towards the importance of underlying altered inflammatory processes (Zhang, et
al., 2015). Different agents that have been documented to be effective against tumors and
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cancers are the agents that function by downregulating important inflammatory pathways
and pro-inflammatory cytokines such as IL1-β, IL-6 and TNF-α, and reduction of
macrophage infiltration (Y. Li, et al., 2012). It has also been shown that the intestinal
commensal bacteria plays a role in the development of immune system of the gut
microenvironment comprising both the humoral and cellular components and maintains
the protective steady state immune function throughout life (Cebra, 1999). It may be more
appropriate to say that any alteration numbers of certain bacteria often lead to upregulation
or downregulation of certain inflammatory pathways. The systemic release of microbial
products as a result of the perturbation of the gut epithelium invokes an IL-23 response and
a further IL-17 response in order to neutralize further invasion by the microbes, and the
process is brought about by the Firmicutes bacteria Clostridia sp. (Shih, et al., 2014). The
bacteria especially promotes IL-17 cytokine in the small intestine which is the primary site
of its attachment and survival (Omenetti & Pizarro, 2015). These Th17 cells may become
autoreactive in case of intestinal epithelium insult. The bacteria Bacteroides fragilis from
the Bacteroidetes phylum leads to an increase in the production of IL-10 cytokine, whereas
its strains have been implicated in the production of the pro-inflammatory cytokine IL-17dependent inflammation-related colon cancer (W. Wu, et al., 2015). Inflammation, which
is an integral part of tumorigenesis should therefore, may strongly be correlated with a
reduced bacterial diversity or numbers.
AIM 3.1: To examine if a change in Bacteroidetes and Firmicutes populations regulate
intestinal goblet cell numbers in ApcMin/+ mice.
AIM 3.2: To examine if a change in Bacteroidetes and Firmicutes populations regulate
systemic levels of cytokines IL-6 and TNF-α in ApcMin/+ mice.
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Experimental Design Specific Aim 3: The experimental design for aim 3 will be the same
as that for aim 2. The experimental animals and groups will be the same as those used for
aim 2.
The first part of aim 3 will be directed towards elucidating the effect of an altered
microbiome on the process of inflammation localized at the level of epithelial lining in the
form of intestinal insult and undesirable infiltration of immune cells at the gut lining.
The second part of aim 3 will elucidate an inflammatory effect of microbiome
dysbiosis which can be studied through the measuring tissue-secreted cytokines as a result
of the aforesaid localized inflammation.
The third part of aim 3 is aimed at studying an inflammatory response of the body
to microbiome dysbiosis at a systemic level.
Material and methods:
Tissue and serum collection: The experimental tissue and serum collected in aim 1 and 2
will also be used in aim 3.

16S rRNA-based Metagenomics
At sacrifice, fecal samples will be obtained from the experimental mice to perform bacterial
(luminal) microbiome analysis. Bacterial n16S rRNA gene amplification and sequencing
will be performed at the Alkek Center for Metagenomics and Microbiome Research,
Department of Molecular Virology and Microbiology, Baylor College of Medicine
(Houston, TX). Polymerase Chain Reaction (PCR) amplification of the V4 region of the
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bacterial 16 S rRNA gene will be performed using the Illumnia Miseq sequencer. The
consensus sequences obtained from the analysis will be mapped into Operational
Taxonomic Units (OTUs). Alpha- and beta-diversity values will be obtained based on the
OTUs’ relative abundance table. Chao1 (estimator of richness) and Shannon Diversity
Index (richness and evenness) will be used to obtain the alpha diversity values. Weighted
Unifrac (dissimilarity based on phylogenetic differences and taxonomic abundance) and
Unweighted Unifrac (dissimilarity based on phylogenetic differences but not abundance)
will be performed to obtain the beta-diversity values for the experimental samples (He, et
al., 2016). Kruskal Wallis and Mann Whitney statistical analyses will be performed to
calculate significance in diversity and relative abundance respectively, by comparing
different treatments and disease stages. A p value of less than 0.05 will be considered
significant.

Hematoxylin and Eosin staining: Paraffin embedded 5 µm sections from aim 2 will be
used for performing Hematoxylin and Eosin staining in order to determine the morphology
of small intestine and colon epithelial layer. Histopathology will be quantified visually in
a double-blind condition using light microscopy. Localized inflammatory status will be
indicated by inflammatory cells present in the mucosal layers of intestine and colon.
Aberrant villi and crypts will also be used as indicators of intestinal and colonic insults due
to inflammatory response.
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Enzyme-linked Immunosorbent Assay (ELISA): Supernatents obtained from 2 mm2
small intestinal tissues kept in RPMI for 24 hours at 37oC will be used to perform ELISA
to quantify small-intestinal secreted pro-inflammatory cytokines IL-1β, IL-17 and TNF-α.
Serum samples obtained from the experimental animals at the time of sacrifice will be used
to quantify systemic levels inflammatory response by measurement of systemic levels of
pro-inflammatory cytokines IL-1β, IL-17 and TNF-α.

Statistical Analysis: Two-way analysis of variance (ANOVA), Two-way repeated
measure ANOVA and One-way ANOVA will be used to analyze the data with Tukey post
hoc-analyses. A p<0.05 will be considered statistically significant. All the statistical
analyses will be done using SigmaStat 3.5 (SPSS, Chicago, IL).

Primary Outcomes:
Relative abundance of Firmicutes and Bacteroidetes
The inflammatory status is often associated with the abundance of Firmicutes population
that tends to further increase the levels of inflammation. Thus, quantifiucation of
Firmicutes will be an important primary outcome of aim 3.
Visually quantifiable levels of mucosal inflammation
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Abnormal infiltration by immune cells at the mucosal layer can be used as a measure to
determine the effect of an altered microbiome on an inflammatory response at the mucosal
level.
Tissue-localized inflammatory response
Certain measurable quantities of pro-inflammatory cytokines can be secreted locally by the
intestinal tissue as a response to either the localized mucosal layer infiltration by immune
cells or due to increased levels of systemic inflammation. 1 cm long sections of small
intestine will be excised from the experimental mice at the time of sacrifice and incubated
in 1 mLl of RPMI buffer in 12-well plates at 37oC overnight. The tissue supernatant will
be centrifuged at 4000 rpm for 10 minutes at 15oC and will be stored at -20oC till analysis.
Systemic inflammatory response
Systemic levels of pro-inflammatory cytokine proteins IL-1β, IL-17 and TNF-α will be
measured to quantify inflammation as a result of perturbed microbiome at systemic levels.
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